Universal cell and preparation method therefor
By reducing MHC-I and MHC-II expression and increasing CD68 protein expression through CRISPR/Cas9 gene editing and lentiviral vector technology, the problem of immune rejection in allogeneic stem cell transplantation was solved, and the preparation of low-immunogenic pluripotent stem cells was achieved, thus improving the safety and efficacy of treatment.
Patent Information
- Application Number
- PCT/CN2024/076898
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-16
- Filing Date
- 2024-02-08
- Publication Date
- 2024-11-14
AI Technical Summary
In existing technologies, allogeneic stem cell transplantation for disease treatment has problems such as immune rejection and immunosuppressant side effects, especially the immune response caused by the expression of MHC-I and MHC-II genes, which hinders its clinical application.
By knocking out the B2M and CIITA genes using CRISPR/Cas9 gene editing technology, reducing the expression of MHC-I and MHC-II, and increasing CD68 protein expression using lentiviral vectors, the sensitivity to NK cells and macrophages was reduced, thus preparing low-immunogenic pluripotent stem cells.
This approach enables the use of pluripotent stem cells in allogeneic transplantation to reduce immune rejection, decrease the need for immunosuppressants, and improve the safety and efficacy of cell therapy.
Smart Images

Figure CN2024076898_14112024_PF_FP_ABST
Abstract
Description
Universal cells and preparation method thereof Technical Field
[0001] The present invention belongs to the field of genetic engineering and stem cell technology, and particularly relates to a universal cell expressing CD68 and a preparation method thereof. Background Art
[0002] Stem cells are a type of "seed" cell with the ability to self-renew and differentiate into specialized somatic cells. Based on the degree of differentiation within these characteristics, stem cells are primarily categorized as totipotent stem cells (totipotent stem cells), pluripotent stem cells (PSCs), and adult stem cells. Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) possess the potential for unlimited proliferation, self-renewal, and differentiation into various cell types, holding great promise for treating cancer, neurological, cardiovascular, and other related diseases.
[0003] Autologous cell transplantation therapy can circumvent the problem of immune rejection, but the process of autologous iPS cell differentiation therapy is complex, expensive, and time-consuming, requiring patients to wait a long time before receiving treatment. In contrast, through in vitro stem cell culture or induced differentiation, healthy functional cells can be regenerated in large quantities in vitro, allowing the transplantation of allogeneic functional cells to treat diseases such as heart disease, including myocardial infarction (MI). However, issues such as immune incompatibility, immune rejection of transplanted cells, and the severe toxic side effects of long-term immunosuppressant therapy have hindered the clinical application of allogeneic functional cell transplantation therapy.
[0004] Therefore, there is an urgent need to develop universal iPS-derived cell therapies that are independent of immunosuppressants to meet the cell needs of regenerative medicine.
[0005] The human major histocompatibility complex (MHC), also known as human leukocyte antigens (HLA), is the primary cause of immune incompatibility. MHC is composed of a series of genes, divided into classes I, II, and III. MHC-I genes are expressed in nearly all tissue cell types. Transplanted cells expressing "non-self" MHC-I molecules stimulate CD8+ T cell activation and are eliminated. CD4+ helper T cells recognize the MHC-II genes of "non-self" cells, leading to immune rejection. Class III molecules, however, do not participate in immune activity.
[0006] In recent years, it has been reported that by knocking out genes such as B2M and CIITA, the expression of MHC-I and MHC-II cell surface or own genes can be lost, thereby making the cells immune tolerant or escaping T cell / B cell-specific immune responses, and producing immune-compatible universal pluripotent stem cells.
[0007] It has been reported that by disrupting the expression of MHC-I and MHC-II class genes, cells can express non-classical HLA-I class molecules such as HLA-E / G, or express immunosuppressive checkpoint proteins such as PD-L1, CTLA4-Ig, CD47, and CD24, which can effectively escape NK cell killing (WO2021041316A1).
[0008] Summary of the Invention
[0009] In a first aspect, the present invention provides a low immunogenic pluripotent stem cell comprising: reduced endogenous major histocompatibility class I antigen (MHC-I) function compared to a parental pluripotent stem cell; reduced endogenous major histocompatibility class II antigen (MHC-II) function compared to a parental pluripotent stem cell; and reduced sensitivity to NK cell killing and / or macrophage killing compared to a parental pluripotent stem cell, wherein the reduced sensitivity to NK cell killing and / or macrophage killing is caused by increased expression of CD68 protein.
[0010] In some embodiments, the MHC-I function is reduced by decreasing the activity of an MHC-I class protein or an MHC-I transcriptional regulator.
[0011] In one embodiment, the MHC-I function is reduced by reducing the activity of the B2M protein.
[0012] In one embodiment, the B2M protein is a human B2M protein, which comprises the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence that is 90% identical to the amino acid sequence shown in SEQ ID NO: 1.
[0013] In one embodiment, the B2M protein is a cynomolgus monkey B2M protein, which comprises the amino acid sequence shown in SEQ ID NO: 9 or an amino acid sequence that has 90% identity with the amino acid sequence shown in SEQ ID NO: 9.
[0014] In some embodiments, the MHC-II function is reduced by reducing the activity of an MHC-II class protein or an MHC-II transcriptional regulator.
[0015] In one embodiment, the MHC-II function is reduced by reducing the activity of the CIITA protein.
[0016] In one embodiment, the CIITA protein is a human CIITA protein comprising the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence having 90% identity with the amino acid sequence shown in SEQ ID NO: 2.
[0017] In one embodiment, the CIITA protein is a cynomolgus monkey CIITA protein comprising the amino acid sequence shown in SEQ ID NO: 10 or an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 10.
[0018] In some embodiments, the CD68 protein is a human CD68 protein comprising the amino acid sequence shown in SEQ ID NO: 3 or an amino acid sequence having 90% identity to the amino acid sequence shown in SEQ ID NO: 3.
[0019] In some embodiments, the CD68 protein is a cynomolgus monkey CD68 protein comprising the amino acid sequence shown in SEQ ID NO:7 or an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:7.
[0020] In one embodiment, the low immunogenic pluripotent stem cells comprise: one or more changes that reduce the activity of endogenous B2M protein; one or more changes that reduce the activity of endogenous CIITA protein; and one or more changes that cause increased expression of CD68 protein in the low immunogenic pluripotent stem cells.
[0021] In one embodiment, the low immunogenic pluripotent stem cells comprise: one or more changes that inactivate both alleles of the endogenous B2M gene; one or more changes that inactivate both alleles of the endogenous CIITA gene; and one or more changes that cause increased expression of the CD68 gene in the low immunogenic pluripotent stem cells.
[0022] In a second aspect, the present invention also provides a method for producing the low immunogenic pluripotent stem cells of the present invention, the method comprising: reducing the endogenous major histocompatibility class I antigen (MHC-I) function in the pluripotent stem cells; reducing the endogenous major histocompatibility class II antigen (MHC-II) function in the pluripotent stem cells; and increasing the expression of a protein that reduces the sensitivity of the pluripotent stem cells to NK cell killing and / or macrophage killing, wherein the protein is CD68 protein.
[0023] In one embodiment, the method comprises: reducing the activity of B2M protein in the pluripotent stem cells; reducing the activity of CIITA protein in the pluripotent stem cells; and increasing the expression of CD68 protein in the pluripotent stem cells.
[0024] In one embodiment, the method comprises: eliminating the activity of both alleles of the B2M gene in the pluripotent stem cells; eliminating the activity of both alleles of the CIITA gene in the pluripotent stem cells; and increasing the expression of the CD68 gene in the pluripotent stem cells.
[0025] In one embodiment, the activity of B2M protein in the pluripotent stem cells is reduced by clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 gene editing technology.
[0026] In one embodiment, the activity of CIITA protein in the pluripotent stem cells is reduced by clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 gene editing technology.
[0027] In one embodiment, expression of CD68 protein is increased by expression of a transgene.
[0028] In a preferred embodiment, a nucleic acid sequence encoding CD68 protein is synthesized and constructed into a lentiviral vector, and then at least one copy of the CD68 gene under the control of a promoter is introduced into the pluripotent stem cells via the lentiviral vector to increase the expression of CD68 protein.
[0029] In one embodiment, the nucleic acid sequence encoding the CD68 protein comprises the nucleic acid sequence shown in SEQ ID NO: 4 or a nucleic acid sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO: 4.
[0030] In one embodiment, the nucleic acid sequence encoding the CD68 protein comprises the nucleic acid sequence shown in SEQ ID NO: 8 or a nucleic acid sequence that is at least 80% identical to the nucleic acid sequence shown in SEQ ID NO: 8.
[0031] In a third aspect, the present invention further provides use of the low immunogenicity pluripotent stem cells of the first aspect or the low immunogenicity pluripotent stem cells prepared by the method of the second aspect in preparing a drug for preventing or treating a disease requiring cell transplantation.
[0032] In a fourth aspect, the present invention further provides a kit for preparing low immunogenic cardiomyocytes, the kit comprising the low immunogenic pluripotent stem cells of the first aspect or the low immunogenic pluripotent stem cells prepared by the method of the second aspect, a first culture medium, a second culture medium, and a third culture medium:
[0033] The first culture medium is a basal culture medium containing a GSK-3 inhibitor; and
[0034] The third culture medium is a basal culture medium containing a Wnt inhibitor.
[0035] In a fifth aspect, the present invention further provides a method for preparing low-immunogenic cardiomyocytes, the method comprising using the kit of the fourth aspect.
[0036] In some embodiments, the method comprises:
[0037] culturing the low immunogenicity pluripotent stem cells in a first culture medium;
[0038] The first culture medium was replaced with the second culture medium, and the cells were continued to be cultured;
[0039] The second culture medium was replaced with the third culture medium, and the cells were continued to be cultured;
[0040] replacing the third culture medium with the second culture medium, and continuing to culture the cells; and
[0041] Obtain differentiated low-immunogenic cardiomyocytes.
[0042] In a sixth aspect, the present invention also provides a method for preparing low immunogenic cardiomyocytes, the method comprising:
[0043] adding a GSK-3 inhibitor to a cardiomyocyte differentiation medium, and culturing the low immunogenicity pluripotent stem cells of the first aspect or the low immunogenicity pluripotent stem cells prepared by the method of the second aspect in the cardiomyocyte differentiation medium supplemented with the GSK-3 inhibitor;
[0044] The cardiomyocyte differentiation medium supplemented with GSK-3 inhibitor was replaced with cardiomyocyte differentiation medium and the cells were continued to be cultured;
[0045] adding a Wnt inhibitor to the cardiomyocyte differentiation medium and continuing to culture the cells in the cardiomyocyte differentiation medium supplemented with the Wnt inhibitor;
[0046] replacing the cardiomyocyte differentiation medium supplemented with Wnt inhibitors with cardiomyocyte differentiation medium and continuing to culture the cells; and
[0047] Obtain differentiated low-immunogenic cardiomyocytes.
[0048] In a seventh aspect, the present invention provides a low immunogenic cardiomyocyte, which is prepared by the kit of the fourth aspect or the method of the fifth aspect or the sixth aspect of the present invention.
[0049] In an eighth aspect, the present invention provides a cell therapeutic agent for preventing or treating heart disease, wherein the cell therapeutic agent comprises the low immunogenic cardiomyocytes according to the seventh aspect of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] FIG1 shows the knockout strategy of the B2M gene in the B2M and CIITA double knockout cell lines (DKO) (A) and the results of B2M gene knockout verification by PCR (B, C).
[0051] FIG2 shows the knockout strategy of the CIITA gene in B2M and CIITA double knockout cell lines (DKO) (A) and the results of CIITA gene knockout verification by PCR (B, C).
[0052] FIG3 shows the results of qPCR detection of the expression of B2M and CIITA at the RNA level in the B2M / CIITA biallelic knockout clone H1 cell line DKO.
[0053] FIG4 shows the results of Western blot detection of B2M protein levels in the B2M / CIITA biallelic knockout clone H1 cell line DKO.
[0054] Figures 5A and 5B show the results of FACS detection of HLA class I / II molecules on the cell surface by stimulating WT and DKO cells of the H1 cell line with IFN-γ; Figures 5C and 5D show the results of FACS detection of HLA class I / II molecules on the cell surface by stimulating WT and DKO cells of the iPS cell line with IFN-γ.
[0055] FIG6 shows the karyotype detection results of the B2M / CIITA biallelic knockout clone H1 cell line DKO cells.
[0056] Figures 7A and 7B show the results of detecting stemness gene expression in H1 cell line DKO cells. Figure 7A shows the results of immunofluorescence detection of the protein levels of the stemness genes POU5F1 and NANOG in H1 cell line WT and DKO cells; Figure 7B shows the results of RT-qPCR detection of the RNA expression of the stemness genes POU5F1, NANOG, and SOX2 in H1 cell line WT and DKO cells.
[0057] Figures 8A-D show the results of immunofluorescence and flow cytometry detection of stemness gene expression in WT and DKO cells of the H1 cell line and iPS cell line. Figure 8A shows the results of flow cytometry detection of the expression of stemness genes SSEA-4 and TRA-1-81 on the surface of H1 cell line WT and DKO cells; Figure 8B shows the results of flow cytometry detection of the expression of stemness genes SSEA-4, TRA-1-60, TRA-1-81, OCT-4, and SOX2 on the surface of iPSC-WT and iPSC-DKO cells; Figure 8C shows the results of immunofluorescence detection of the protein levels of stemness genes TRA-1-60, TRA-1-81, OCT-4, SOX2, and NANOG in iPSC-WT cells; Figure 8D shows the results of immunofluorescence detection of the protein levels of stemness genes TRA-1-60, TRA-1-81, OCT-4, SOX2, and NANOG in iPSC-DKO cells.
[0058] FIG9 shows the results of hematoxylin and eosin staining to detect the differentiation ability of B2M / CIITA biallelic knockout H1 cell line DKO cells to form teratomas in vivo and differentiate into cells of the endometrium, mesoderm, and ectoderm.
[0059] Figure 10A shows the results of verifying the immune function of H1 cell line WT and DKO cells using RTCA detection; the three figures in the first row are the results of RTCA detection of the killing rate of NK cells on H1 cell line WT and DKO cells, that is, the detection results of the immune escape function of H1 cell line WT and DKO cells on NK cells; the three figures in the second row are the results of RTCA detection of the killing rate of T cells on H1 cell line WT and DKO cells, that is, the detection results of the immune escape function of H1 cell line WT and DKO cells on T cells. Figure 10B shows the results of validating the immune function of iPS cell lines WT and DKO using RTCA detection; the first row of three figures shows the results of RTCA detection of the killing rate of NK cells against iPSC-WT and iPSC-DKO cells, i.e., the detection results of the immune escape function of iPSC-WT and iPSC-DKO cells against NK cells; the second row of three figures shows the results of RTCA detection of the killing rate of T cells against iPSC-WT and iPSC-DKO cells, i.e., the detection results of the immune escape function of iPSC-WT and iPSC-DKO cells against T cells;
[0060] FIG11 shows a schematic diagram of the structure of the lentiviral vector pGC-EF1a.
[0061] Figures 12A and 12B show the results of validating the overexpression of CD47 in H1 cell line DKO+CD47 cells. Figure 12A shows the results of detecting the expression level of CD47 in H1 cell line DKO+CD47 cells by FACS; Figure 12B shows the results of detecting the expression level of CD47 in H1 cell line DKO+CD47 cells by qPCR.
[0062] FIG13 shows the results of detecting the immune escape function of H1 cell line WT and DKO+CD47 cells by RTCA.
[0063] FIG. 14 shows the results of RT-PCR detection of the overexpression level of mRNA in the constructed H1 cell line DKO+CD68 cells.
[0064] Figures 15A and 15B show the results of detecting the stemness of H1 cell line DKO+CD68 cells. Figure 15A shows the results of immunofluorescence detection of the protein levels of stemness genes OCT4, NANOG, SOX2, TRA-1-60, and TRA-1-81 in constructed H1 cell line DKO+CD68 cells; Figure 15B shows the results of flow cytometry detection of the expression levels of cell surface stemness genes SSEA-4, TRA-1-60, TRA-1-81, and OCT4 in constructed H1 cell line DKO+CD68 cells.
[0065] FIG. 16 shows the results of immunofluorescence detection of the three-germ layer differentiation ability of the constructed H1 cell line DKO+CD68 cells.
[0066] FIG. 17 shows the results of testing the teratoma-forming ability of H1 cell line DKO+CD68 cells.
[0067] Figures 18A, 18B, 18C, and 18D show the results of NK cell cytotoxicity experiments against H1 cell line DKO+CD68 cells and iPS cell line DKO+CD68 cells detected by RTCA. Figure 18A shows the results of the cytotoxicity experiment against H1 cell line DKO+CD68 cells, and Figure 18B shows the statistical graph of multiple cytotoxicity against H1 cell line DKO+CD68 cells, N=12; Figure 18C shows the results of the cytotoxicity experiment against iPS cell line DKO+CD68 cells, and Figure 18D shows the statistical graph of multiple cytotoxicity against iPS cell line DKO+CD68 cells, N=4.
[0068] Figures 19A, 19B, 19C, and 19D show the results of an RTCA-based T cell + NK cell cytotoxicity experiment against DKO + CD68 cells. Figure 19A shows the results of an H1 cell line cytotoxicity experiment against DKO + CD68 cells, and Figure 19B shows a statistical graph of multiple cytotoxicity against H1 cell line DKO + CD68 cells, with N = 4. Figure 19C shows the results of an iPS cell line cytotoxicity experiment against DKO + CD68 cells, and Figure 19D shows a statistical graph of multiple cytotoxicity against iPS cell line DKO + CD68 cells, with N = 2.
[0069] Figures 20A and 20B show the results of a macrophage cytotoxicity experiment against DKO+CD68 cells detected by RTCA. Figure 20A shows the results of a cytotoxicity experiment on the H1 cell line DKO+CD68 cells, and Figure 20B shows a statistical graph of multiple cytotoxicity analyses on the H1 cell line DKO+CD68 cells. N=8 for each of the H1 cell line WT and DKO cell groups, and N=6 for each of the H1 cell line DKO+CD47 and DKO+CD68 cell groups.
[0070] FIG21 shows the cell status of the constructed H1 cell line DKO+CD68 cells after co-culture with NK cells for 24 hours.
[0071] 22A and 22B show the results of ELISpot detection of IFN-γ spot secretion by H1 cell line DKO+CD68 cells constructed after co-culture with NK cells for 24 hours, wherein FIG22B is a statistical histogram of IFN-γ spot frequency.
[0072] FIG23A and FIG23B show the results of RTCA detection of the NK cell escape function of differentiated cells of the constructed H1 cell line DKO+CD68 cells, wherein FIG23B is a statistical diagram of multiple killing, N=6.
[0073] Figures 24A and 24B show the results of the escape function of differentiated cells of the H1 cell line DKO+CD68 cells constructed by RTCA detection against T cells+NK cells, wherein Figure 24B is a multiple killing statistical graph, N=8 for each group of H1 cell line WT and DKO cells, and N=4 for the H1 cell line DKO+CD68 cell group.
[0074] 25A and 25B show the results of RTCA detection of the escape function of differentiated cells of the constructed H1 cell line DKO+CD68 cells against macrophages, wherein FIG25B is a statistical diagram of multiple killing, N=10.
[0075] FIG26A shows the results of immunofluorescence detection of stemness gene protein levels in NHP iPSC-DKO cells; FIG26B shows by immunohistochemistry that NHP iPSC-DKO cells can form teratomas with endogenous, mesodermal, and ectodermal germ layers.
[0076] FIG27 shows the results of FACS detection of HLA class I / II molecules on the cell surface by stimulating NHP iPSC-WT (ie, NHP WT) and NHP iPSC-DKO cells (ie, NHP DKO1 and NHP DKO2) with IFN-γ.
[0077] FIG28 shows the results of an experiment detecting the killing ability of cynomolgus monkey T cells against NHP iPSC-WT (ie, NHP WT), NHP iPSC-DKO1 (ie, NHP DKO1), and NHP iPSC-DKO2 (ie, NHP DKO2) cells by RTCA.
[0078] FIG. 29 shows the results of detecting the expression level of CD68 in NHP iPSC-DKO+CD68 cells by RT-qPCR.
[0079] Figure 30 shows the results of the RTCA detection of the killing ability of cynomolgus monkey NK cells on NHP iPSC-WT (i.e., NHP WT), NHP iPSC-DKO (i.e., NHP DKO) and NHP iPSC-DKO+CD68 overexpressing CD68 protein (i.e., NHP DKO+CD68), N=4.
[0080] Figure 31 shows the results of the RTCA detection of the killing ability of activated cynomolgus monkey PBMCs on NHP iPSC-WT (i.e., NHP WT), NHP iPSC-DKO (i.e., NHP DKO) and NHP iPSC-DKO+CD68 overexpressing CD68 protein (i.e., NHP DKO+CD68), N=4.
[0081] Figure 32 (A) shows the fluorescence imaging results of transplanted cells in NHPs. Figure 32 (B) shows the fluorescence imaging results of transplanted cells in NOG mice.
[0082] Figure 33 shows the degree of activation of the NHP immune system by transplanted cells. The results of ELISpot detection of spots formed by IFN-γ secreted by crab-eating macaque immune cells after the constructed NHP iPSC-WT and NHP iPSC-DKO+CD68 cells overexpressing CD68 protein were injected into NHP, and are displayed as a statistical histogram of the IFN-γ spot frequency.
[0083] Figure 34 shows a schematic diagram of the process of differentiating WT cells and DKO+CD68 cells of the iPS cell line into iCMs (i.e., hiPSCs-CMs) in vitro. Days -2 to 0 are the hiPSC culture stage, and the cell culture medium used is mTESR1; Days 0-15 are the cardiomyocyte induction stage, and the cell culture medium used is PRMI1640 supplemented with B27 without insulin, and the cells are induced with the GSK3 inhibitor CHIR99021 and the Wnt inhibitor IWR-1 respectively; Days 15-30 are the cardiomyocyte maintenance stage, and the cell culture medium used is PRMI1640 supplemented with B27 containing insulin.
[0084] Figure 35 (A) shows a bright field schematic diagram and flow cytometry results of cells derived from the iPS cell line WT cell group and the DKO+CD68 cell group at D15 of induction differentiation; Figure 35 (B) shows a bright field schematic diagram and flow cytometry results of cells derived from the iPS cell line WT cell group and the DKO+CD68 cell group at D30 of induction differentiation; the left sides are both bright field schematic diagrams, and the right side is the results of flow cytometry detection of cTnT positivity rate.
[0085] FIG36 shows the results of quantitative fluorescence PCR detection of the expression of cardiomyocyte-related genes in cells derived from the iPS cell line WT cell group and the DKO+CD68 cell group on day 30 of differentiation induction.
[0086] FIG37 shows the results of calcium transient detection in iCMs derived from iPS cell lines WT cells and DKO+CD68 cells.
[0087] FIG38 shows the results of validating the efficacy of universal stem cell-derived iCMs in a permanent ligation mouse myocardial infarction model using cardiac ultrasound functional testing.
[0088] FIG39 shows the results of FACS analysis of HLA class I / II molecules on the cell surface using IFN-γ to stimulate iCMs derived from the iPS cell line WT cells and DKO+CD68 cells.
[0089] FIG40 shows the results of an experiment in which PBNK cells were used to detect the killing ability of iCMs differentiated from iPS cell lines WT cells and DKO+CD68 cells by RTCA.
[0090] FIG. 41 shows surviving cells after killing of iCMs differentiated from iPS cell lines WT cells and DKO+CD68 cells using PBNK cells.
[0091] FIG42 shows the in vitro detection of the activation ability of iCMs differentiated from iPS cell lines WT cells and DKO+CD68 cells on PBMCs by detecting CFSE signal values using FACS. Specific implementation plan
[0092] General Definitions and Terminology
[0093] All patents, patent applications, scientific publications, manufacturer's instructions and guidelines, etc., cited herein, whether supra or infra, are hereby incorporated by reference in their entirety. Nothing herein should be construed as an admission that the present disclosure is not entitled to antedate such publication.
[0094] Unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the terms related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, and microbiology used herein are terms widely used in the corresponding fields (see, for example, Molecular Cloning: A Laboratory Manual, 2 nd Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989). Meanwhile, for a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0095] As used herein, the expressions "comprise," "include," "contain," and "have" are open ended and mean the inclusion of the listed elements, steps, or components but not the exclusion of other unlisted elements, steps, or components. The expression "consisting of excludes any element, step, or component not specified. The expression "consisting essentially of means that the scope is limited to the specified elements, steps, or components, plus optional elements, steps, or components that do not significantly affect the basic and novel properties of the claimed subject matter. It should be understood that the expressions "consisting essentially of" and "consisting of are encompassed within the meaning of the expression "comprising."
[0096] As used herein, the singular forms "a," "an," or "the" include plural referents unless the context indicates otherwise. The terms "one or more" or "at least one" encompass 1, 2, 3, 4, 5, 6, 7, 8, 9 or more.
[0097] Recitation of ranges of values herein is intended merely to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated into the specification as if it were individually recited herein. Unless expressly indicated to the contrary, values or ranges recited herein are modified by "about" to mean ±20%, ±10%, ±5%, or ±3% of the recited or claimed value or range.
[0098] Unless otherwise specified, the labels such as 1), 2), ..., i), ii), a), b), ... in the method steps described herein are merely examples of distinction and do not imply that the method steps described herein are performed in such order.
[0099] The term "pluripotent cell" refers to a cell that is capable of self-renewal and proliferation while remaining in an undifferentiated state and that can be induced to differentiate into specialized cell types under appropriate conditions.
[0100] As used herein, the term "pluripotent stem cell" has the potential to differentiate into any one of the following three germ layers: endoderm (e.g., gastric junction, gastrointestinal tract, lung, etc.), mesoderm (e.g., muscle, bone, blood, urogenital tissue, etc.), or ectoderm (e.g., epidermal tissue and nervous system tissue). The term "pluripotent stem cell" as used herein also includes "induced pluripotent stem cells" or "iPSCs," a pluripotent stem cell derived from a non-pluripotent cell. Exemplary human pluripotent stem cell lines include iPS cells, H1 human pluripotent stem cell lines, and H9 human pluripotent stem cell lines. Additional exemplary pluripotent stem cell lines include those available through the National Institutes of Health Human Embryonic Stem Cell Registry and the Howard Hughes Medical Institute HUES collection (e.g., Cowan CA, et al. Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med. 2004 Mar 25; 350 (13): 1353-6. described).
[0101] As used herein, the term "totipotent" refers to the ability of a cell to form a complete organism. For example, in mammals, only the zygote and the first cleavage stage blastomere are totipotent. In one embodiment, the pluripotent stem cells described herein do not have totipotency and will not form a complete organism.
[0102] As used herein, the term "universal cells" refers to cells that are modified using gene editing technology to eliminate immune rejection and achieve universalization.
[0103] The cells can be from, for example, humans or non-human mammals. Exemplary non-human mammals include, but are not limited to, mice, rats, cats, dogs, rabbits, guinea pigs, hamsters, sheep, pigs, horses, cattle, and non-human primates. In some embodiments, the cells are from adults or non-human mammals. In some embodiments, the cells are from newborn humans, adults, or non-human mammals.
[0104] As used herein, the term "immune rejection" or "immune incompatibility" refers to the inability of allogeneic cells, tissues, or organs to function properly after transplantation to a recipient due to attack by the recipient's own immune cells. The human major histocompatibility complex (MHC), also known as human leukocyte antigens (HLA), is the primary cause of "immune rejection" or "immune incompatibility."
[0105] As used herein, the term "subject" or "patient" refers to any animal, such as a domesticated animal, a zoo animal, or a human. A "subject" or "patient" can be a mammal, such as a dog, a cat, a bird, livestock, or a human. Specific examples of "subjects" and "patients" include, but are not limited to, individuals (particularly humans) with diseases or conditions related to the liver, heart, lungs, kidneys, pancreas, brain, nervous tissue, blood, bones, bone marrow, and the like.
[0106] " Hypoimmunogenic pluripotent stem cells " herein refer to pluripotent stem cells, which retain the characteristics of their pluripotent stem cells and produce a reduced immune rejection reaction when transferred to an allogeneic host. In a preferred embodiment, the hypoimmunogenic pluripotent stem cells do not produce an immune response. Therefore, " hypoimmunogenicity " refers to an immune response that is significantly reduced or eliminated compared to the immune response of the parent (" WT ") stem cell before immune modification. For example, relative to wild-type cells that have not been immune modified, this hypoimmunogenic cell may be about 2.5%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99% or more than 99% less likely to produce immune rejection.
[0107] The term "major histocompatibility complex (MHC)" refers to a gene complex found in all vertebrates. MHC proteins or molecules function in signaling between lymphocytes and antigen-presenting cells during normal immune responses. The human MHC, also known as HLA (human leukocyte antigen), is located on chromosome 6 and includes MHC-I and MHC-II.
[0108] The terms "MHC-I" or "MHC class I" refer to major histocompatibility complex class I proteins or genes. Within the human MHC-I region are the HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, CD1a, CD1b, and CD1c subregions. MHC class I proteins are found on the surface of virtually all cells, including most tumor cells. MHC-I proteins are loaded with antigens, which are usually derived from endogenous proteins or pathogens present within the cell, and then presented to cytotoxic T lymphocytes (CTLs, also known as CD8+ T cells). T cell receptors are able to recognize and bind peptides complexed with MHC-I molecules. Each cytotoxic T lymphocyte expresses a unique T cell receptor that is capable of binding to a specific MHC / peptide complex. MHC class I molecules primarily mediate the presentation of endogenous antigens.
[0109] The term "MHC-II" or "MHC class II" refers to major histocompatibility complex class II proteins or genes. MHC II includes five proteins: HLA-DP, HLA-DM, HLA-DOB, HLA-DQ, and HLA-DR. MHC class II proteins are primarily expressed on antigen-presenting cells such as B cells, monocytes, macrophages, and dendritic cells. MHC class II molecules primarily mediate the presentation of exogenous antigens. They present exogenous antigen peptide molecules to Th cells (helper T cells), which stimulate CD4+ T cells.
[0110] The term "MHC / peptide complex" relates to a non-covalent complex of a binding domain of an MHC class I or MHC class II molecule and an MHC class I or MHC class II binding peptide.
[0111] "Knockout" herein refers to the process of making a specific gene inactive in the host cell in which it is located, which results in the non-production of the target protein or an inactive form. As will be appreciated by those skilled in the art and described further below, this can be achieved in a variety of different ways, including removing the nucleic acid sequence from the gene, or interrupting the sequence with other sequences, changing the reading frame, or changing the regulatory elements of the nucleic acid. For example, all or part of the coding region of the target gene can be removed or replaced with a "nonsense" sequence, all or part of the regulatory sequence (e.g., promoter) can be removed or replaced, the translation initiation sequence, etc. can be removed or replaced.
[0112] In this article, the terms "reduce" and "reduce" are generally used to represent a statistically significant amount of reduction. However, for the avoidance of doubt, "reduce", "reduce" include reducing by at least 10% compared to a reference level, such as reducing by at least about 20% or at least about 30% compared to a reference level, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including 100% reduction (i.e., a level that is not present compared to a reference sample), or any reduction between 10-100%.
[0113] As used herein, "knock-in" or "overexpression" refers to the process of adding a genetic function to a host cell. This results in an increase in the level of the encoded protein. As will be appreciated by those skilled in the art, this can be achieved in several ways, including adding one or more additional copies of a gene to the host cell or altering the regulatory components of an endogenous gene to increase protein expression. This can be achieved by modifying the promoter, adding a different promoter, adding an enhancer, or modifying other gene expression sequences.
[0114] As used herein, the term "increase" is generally used to refer to an increase by a statistically significant amount; for the avoidance of any doubt, the term "increase" refers to an increase of at least 10% compared to a reference level, such as an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including a 100% increase or any increase between 10-100%, or at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold or at least about 10-fold compared to a reference level, or any increase between 2-fold and 10-fold or greater than 10-fold.
[0115] The beta-2 microglobulin, or β2M or B2M protein, is a component of MHC class I. B2M is expressed by all nucleated cells (except red blood cells) and can non-covalently bind to the α chain of MHC class I molecules, attaching to cell membranes and being released into various tissue fluids.
[0116] "CD47 protein" or "Integrin-associated protein (IAP)" is an important self-signal that can inhibit the phagocytic function of macrophages and cause immune escape by binding to the N-terminus of the ligand signal regulatory protein α (SIRPα) on immune cells.
[0117] "MHC-II transactivator protein (CIITA) protein" is a key molecule that regulates MHC-II expression. The body mainly regulates the expression level of MHC II genes by controlling the expression of CIITA.
[0118] "CD68 protein" is a transmembrane glycoprotein that can be highly expressed in human monocytes and macrophages. It is a member of the lysosome / endosome-associated membrane glycoprotein (LAMP) family. CD68 protein is mainly localized in lysosomes and endosomes. It is a type I integral membrane protein with a highly glycosylated extracellular domain and binds to tissue and organ-specific lectins or selectins. CD68 protein is also a member of the scavenger receptor family (ScR), which generally has the function of clearing cell debris, promoting phagocytosis, and mediating macrophage recruitment and activation. CD68 protein can play a role in intracellular lysosomal metabolism and extracellular cell-cell and cell-pathogen interactions, in the phagocytic activity of tissue macrophages, and is a commonly used macrophage marker.
[0119] Macrophages are important effector proteins of cellular immunity and are one of the three types of phagocytes, along with granulocytes and dendritic cells. They participate in the recognition, phagocytosis, and degradation of cell debris and pathogens, killing pathogens and tumor cells, and playing a vital role in immune and inflammatory responses. Furthermore, macrophages play a role in maintaining tissue homeostasis and in tissue repair and remodeling.
[0120] As used herein, the term "syngeneic" refers to the genetic similarity or identity of the host organism and the cell transplant, wherein there is immunological compatibility; eg, no immune response is generated.
[0121] As used herein, the term "allogeneic" refers to the genetic differences of the host organism and cells transplanted in which an immune response is generated.
[0122] As used herein, the term "B2M- / -" refers to a diploid cell having an inactivated B2M gene in both chromosomes.
[0123] As used herein, the term "CIITA- / -" refers to a diploid cell having an inactivated CIITA gene in both chromosomes.
[0124] As used herein, the term "polypeptide" refers to a polymer comprising two or more amino acids covalently linked by peptide bonds. A "protein" may comprise one or more polypeptides, wherein the polypeptides interact with each other through covalent or non-covalent means. Unless otherwise indicated, "polypeptide" and "protein" are used interchangeably.
[0125] In the context of cells, "wild type" refers to cells found in nature. However, in the context of pluripotent stem cells, as used herein, it also refers to pluripotent stem cells that have not undergone gene editing procedures to achieve low immunogenicity, for example, the parental pluripotent stem cells (WT) described herein.
[0126] As used herein, the term "% identity" with respect to sequences refers to the percentage of identical nucleotides or amino acids in an optimal alignment between the sequences to be compared. The differences between the two sequences can be distributed over local regions (segments) or over the entire length of the sequences to be compared. The identity between the two sequences is usually determined after optimal alignment of a segment or "comparison window." Optimal alignment can be performed manually, or by means of algorithms known in the art, including but not limited to the local homology algorithm described by Smith and Waterman, 1981, Ads App. Math. 2,482 and Neddleman and Wunsch, 1970, J. Mol. Biol. 48,443, the search for similarity method described by Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88,2444, or using computer programs such as GAP, BESTFIT, FASTA, BLAST P, BLAST N, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis. For example, the percent identity of two sequences can be determined using the publicly available BLASTN or BLASTP algorithms available on the National Center for Biotechnology Information (NCBI) website.
[0127] In some embodiments, the % homogeneity is given in the region of at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or about 100%. In some embodiments, the homogeneity is given to the whole length of the reference sequence. The comparison of sequence homogeneity can be determined with instruments known in the art, preferably using optimal sequence alignment, for example, using Align, using standard settings, preferably EMBOSS::needle, Matrix:Blosum62, Gap Open 10.0, Gap Extend 0.5.
[0128] As used herein, "nucleotides" include deoxyribonucleotides and ribonucleotides and their derivatives. As used herein, "ribonucleotides" are constituents of ribonucleic acid (RNA), consisting of one base molecule, one pentose molecule, and one phosphate molecule. They refer to nucleotides with a hydroxyl group at the 2' position of the β-D-ribofuranosyl group. "Deoxyribonucleotides" are constituents of deoxyribonucleic acid (DNA), also consisting of one base molecule, one pentose molecule, and one phosphate molecule. They refer to nucleotides in which the hydroxyl group at the 2' position of the β-D-ribofuranosyl group is replaced by hydrogen, and are the main chemical components of chromosomes. "Nucleotides" are usually referred to by a single letter representing the base: "A (a)" refers to deoxyadenosine or adenylate containing adenine, "C (c)" refers to deoxycytidine or cytidine containing cytosine, "G (g)" refers to deoxyguanosine or guanylate containing guanine, "U (u)" refers to uridine or uridylate containing uracil, and "T (t)" refers to deoxythymidylate containing thymine.
[0129] As used herein, the terms "polynucleotide" and "nucleic acid" are used interchangeably to refer to a polymer of deoxyribonucleotides (deoxyribonucleic acid, DNA) or a polymer of ribonucleotides (ribonucleic acid, RNA). "Polynucleotide sequence," "nucleic acid sequence," and "nucleotide sequence" are used interchangeably to refer to the order of nucleotides in a polynucleotide. It will be understood by those skilled in the art that a DNA coding strand (sense strand) and the RNA it encodes can be considered to have the same nucleotide sequence, with deoxythymidylic acid in the DNA coding strand sequence corresponding to uridine in the RNA sequence it encodes.
[0130] As used herein, the term "expression" includes transcription and / or translation of a nucleotide sequence. Thus, expression can involve the production of transcripts and / or polypeptides. The term "transcription" refers to the process by which the genetic code in a DNA sequence is transcribed into RNA (transcript). The term "in vitro transcription" refers to the in vitro synthesis of RNA, particularly mRNA, in a cell-free system (e.g., in an appropriate cell extract) (see, e.g., Pardi N., Muramatsu H., Weissman D., Karikó K. (2013). In: Rabinovich P. (eds) Synthetic Messenger RNA and Cell Metabolism Modulation. Methods in Molecular Biology (Methods and Protocols), vol 969. Humana Press, Totowa, NJ.). A vector that can be used to produce a transcript is also referred to as a "transcription vector," which contains regulatory sequences required for transcription. The term "transcription" encompasses "in vitro transcription."
[0131] As used herein, "encoding" refers to the inherent property of a specific nucleotide sequence within a polynucleotide, such as a gene, cDNA, or mRNA, which can serve as a template for the synthesis of polymers and macromolecules involved in other biological processes, given a well-defined nucleotide sequence or amino acid sequence. Thus, a gene encoding a protein means that the gene's mRNA, through transcription and translation, produces the protein in a cell or other biological system.
[0132] As used herein, the terms "first culture medium" and similarly used terms such as "second culture medium," "third culture medium," "fourth culture medium," "fifth culture medium," and "sixth culture medium" are used solely for differentiation purposes and are not intended to limit the order in which these media are used. These terms may be the same or different in different protocols.
[0133] Unless otherwise stated, all methods described herein can be performed in any suitable order.
[0134] pluripotent stem cells
[0135] In a first aspect, the present invention provides a low immunogenicity pluripotent stem cell, comprising:
[0136] reduced endogenous major histocompatibility class I antigen (MHC-I) function compared to parental pluripotent stem cells;
[0137] Reduced endogenous major histocompatibility class II antigen (MHC-II) function compared to the parental pluripotent stem cell; and
[0138] Reduced sensitivity to NK cell killing, T cell killing, and / or macrophage killing compared to the parental pluripotent stem cell.
[0139] Herein, parental pluripotent stem cells refer to parental pluripotent stem cells (also referred to herein as “WT”) before immune modification, which have not undergone a gene editing procedure to achieve low immunogenicity.
[0140] In a preferred embodiment, the decreased sensitivity to NK cell killing or macrophage killing is caused by increased expression of CD68 protein.
[0141] In a preferred embodiment, the reduced sensitivity to NK cell killing and macrophage killing is caused by increased expression of CD68 protein.
[0142] As will be appreciated by those skilled in the art, reduction of function can be achieved in a variety of ways, including removing nucleic acid sequences from a gene, interrupting sequences with other sequences, or altering regulatory components of the nucleic acid. For example, all or part of the coding region of the target gene can be removed or replaced with a "nonsense" sequence, frameshift mutations can be performed, all or part of regulatory sequences, such as promoters, can be removed or replaced, translation initiation sequences can be deleted or replaced, etc.
[0143] As will be appreciated by those skilled in the art, the reduction in MHC I (HLA I when the cells are derived from human cells) function in pluripotent stem cells can be measured using techniques known in the art and described below; for example, FACS techniques using labeled antibodies that bind to the HLA complex; for example, commercially available HLA-A, HLA-B, HLA-C antibodies that bind to human major histocompatibility HLA class I. The reduction in MHC II (HLA II when the cells are derived from human cells) function in pluripotent stem cells can be measured using techniques known in the art and described below; for example, FACS techniques using labeled antibodies that bind to the HLA complex; for example, commercially available HLA-DQ, HLA-DR, HLA-DP antibodies that bind to human major histocompatibility HLA class II.
[0144] In some embodiments, the MHC-I function is reduced by reducing the activity of MHC class I proteins.
[0145] In one embodiment, the MHC class I protein comprises a human leukocyte antigen-A (HLA-A) protein, a human leukocyte antigen-B (HLA-B) protein, or a human leukocyte antigen-C (HLA-C) protein.
[0146] In some embodiments, the MHC-I function is reduced by reducing the activity of an MHC-I transcriptional regulator. In some preferred embodiments, the MHC-I transcriptional regulator can be selected from one or more of: beta 2 microglobulin (B2M), transporter associated with antigen processing 1 (TAP1), transporter associated with antigen processing 2 (TAP2), transporter associated with antigen processing (TAP)-associated glycoprotein (Tapasin), or NOD-like receptor family caspase recruitment domain 5 (NLRC5).
[0147] In one embodiment, the MHC-I function is reduced by reducing the activity of the HLA-A protein.
[0148] In one embodiment, the MHC-I function is reduced by knocking out the gene encoding the HLA-A protein.
[0149] In one embodiment, the MHC-I function is reduced by reducing the activity of an HLA-B protein.
[0150] In one embodiment, the MHC-I function is reduced by knocking out the gene encoding the HLA-B protein.
[0151] In one embodiment, the MHC-I function is reduced by reducing the activity of the HLA-C protein.
[0152] In one embodiment, the MHC-I function is reduced by knocking out the gene encoding the HLA-C protein.
[0153] In one embodiment, the MHC-I function is reduced by reducing the activity of TAP1 protein.
[0154] In one embodiment, the MHC-I function is reduced by knocking out the gene encoding the TAP1 protein.
[0155] In one embodiment, the MHC-I function is reduced by reducing the activity of the TAP2 protein.
[0156] In one embodiment, the MHC-I function is reduced by knocking out the gene encoding the TAP2 protein.
[0157] In one embodiment, the MHC-I function is reduced by reducing the activity of the Tapasin protein.
[0158] In one embodiment, the MHC-I function is reduced by knocking out the gene encoding the Tapasin protein.
[0159] In one embodiment, the MHC-I function is reduced by reducing the activity of the NLRC5 protein.
[0160] In one embodiment, the MHC-I function is reduced by knocking out the gene encoding the NLRC5 protein.
[0161] In a preferred embodiment, the MHC-I function is reduced by reducing the activity of the B2M protein.
[0162] In one embodiment, the B2M protein is a human B2M protein, which comprises the amino acid sequence shown in SEQ ID NO:1 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO:1.
[0163] In one embodiment, the B2M protein is a cynomolgus monkey B2M protein, which comprises the amino acid sequence shown in SEQ ID NO:9 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO:9.
[0164] In one embodiment, the MHC-I function is reduced by knocking out the gene encoding the B2M protein.
[0165] In some embodiments, the MHC-II function is reduced by reducing the activity of an MHC class II protein.
[0166] In one embodiment, the MHC class II protein comprises a human leukocyte antigen-DR (HLA-DR) protein, a human leukocyte antigen-DQ (HLA-DQ) protein, or a human leukocyte antigen-DP (HLA-DP) protein.
[0167] In some embodiments, the MHC-II function is reduced by reducing the activity of an MHC-II transcriptional regulator. In some preferred embodiments, the MHC-II transcriptional regulator can be selected from one or more of: MHC-II transactivator protein (CIITA), regulatory factor X-associated anchor protein (RFXANK), regulatory factor X5 (RFX5), and regulatory factor X-associated protein (RFXAP).
[0168] In one embodiment, the MHC-II function is reduced by reducing the activity of the HLA-DR protein.
[0169] In one embodiment, the MHC-II function is reduced by knocking out the gene encoding the HLA-DR protein.
[0170] In one embodiment, the MHC-II function is reduced by reducing the activity of the HLA-DQ protein.
[0171] In one embodiment, the MHC-II function is reduced by knocking out the gene encoding the HLA-DQ protein.
[0172] In one embodiment, the MHC-II function is reduced by reducing the activity of the HLA-DP protein.
[0173] In one embodiment, the MHC-II function is reduced by knocking out the gene encoding the HLA-DP protein.
[0174] In one embodiment, the MHC-II function is reduced by reducing the activity of the RFXANK protein.
[0175] In one embodiment, the MHC-II function is reduced by knocking out the gene encoding the RFXANK protein.
[0176] In one embodiment, the MHC-II function is reduced by reducing the activity of the RFX5 protein.
[0177] In one embodiment, the MHC-II function is reduced by knocking out the gene encoding the RFX5 protein.
[0178] In one embodiment, the MHC-II function is reduced by reducing the activity of the RFXAP protein.
[0179] In one embodiment, the MHC-II function is reduced by knocking out the gene encoding the RFXAP protein.
[0180] In a preferred embodiment, the MHC-II function is reduced by reducing the activity of the CIITA protein.
[0181] In one embodiment, the CIITA protein is a human CIITA protein comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 2.
[0182] In one embodiment, the CIITA protein is a cynomolgus monkey CIITA protein, which comprises the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 10.
[0183] In one embodiment, the MHC-II function is reduced by knocking out the gene encoding the CIITA protein.
[0184] In a preferred embodiment, CRISPR technology is used to knock out a gene. In some cases, CRISPR technology is used to introduce small deletions / insertions into the coding region of a gene so that no functional protein is produced, usually as a result of a frameshift mutation, which results in the generation of a stop codon, resulting in a truncated, non-functional protein.
[0185] The successful reduction of MHC-I (HLA-I when the cells are derived from human cells) function and MHC-II (HLA-II when the cells are derived from human cells) function in pluripotent stem cells can be measured using techniques known in the art, such as Western blotting using protein antibodies, FACS technology, RT-PCR, qPCR technology, etc.
[0186] In some embodiments, the reduced sensitivity to NK cell killing and / or macrophage killing is caused by increased expression of CD68 protein in pluripotent stem cells. This is accomplished in several ways, as will be appreciated by those skilled in the art, and can use "knock-in" or transgenic technology. In some cases, increased CD68 expression is caused by one or more CD68 transgenes.
[0187] Thus, in some embodiments, one or more copies of the CD68 gene are added to pluripotent stem cells under the control of an inducible or constitutive promoter. In some embodiments, a lentiviral construct is used as described herein or known in the art. As known in the art, the CD68 gene can be integrated into the genome of the host cell under the control of a suitable promoter.
[0188] In one embodiment, the increased CD68 protein expression is caused by CD68 transgene or CD68 gene knock-in.
[0189] In one embodiment, the CD68 protein is a human CD68 protein, which comprises the amino acid sequence shown in SEQ ID NO:3 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO:3.
[0190] In one embodiment, the CD68 protein is a cynomolgus monkey CD68 protein, which comprises the amino acid sequence shown in SEQ ID NO:7 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO:7.
[0191] The presence of sufficient CD68 protein expression can be determined using known techniques, such as those described in the Examples, for example, using Western blot, ELISA assay, or FACS assay. Typically, "sufficient" in this context means an increase in CD68 protein expression on the surface of pluripotent stem cells that silences NK cell killing and / or macrophage killing.
[0192] In another aspect, the present invention further provides a low immunogenic pluripotent stem cell comprising:
[0193] One or more changes that reduce the activity of endogenous B2M protein;
[0194] One or more changes that reduce the activity of endogenous CIITA protein; and
[0195] One or more alterations result in increased expression of CD68 protein in the poorly immunogenic pluripotent stem cells.
[0196] In one embodiment, the low immunogenic pluripotent stem cells comprise:
[0197] one or more alterations that inactivate both alleles of the endogenous B2M gene;
[0198] One or more alterations that inactivate both alleles of the endogenous CIITA gene; and
[0199] One or more alterations result in increased CD68 gene expression in the low immunogenic pluripotent stem cells.
[0200] As used herein, the term "change" or "hereditary alteration" refers to causing a cell, such as a change in pluripotent stem cells as described herein, which can be achieved, for example, by modifying a genome or introducing a new gene fragment. In this article, modifying a genome refers to modifying the nucleic acid sequence in a cell or under a cell-free condition to produce transformed pluripotent cells and pluripotent stem cells. The technology of exemplary "change" or "hereditary alteration" includes but is not limited to homologous recombination, knocking in, ZFN (zinc finger nuclease), TALEN (transcription activator-like effector nuclease), CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 and other site-specific nuclease technologies. These technologies enable double-stranded DNA breaks to be carried out at the desired gene locus. These controlled double-strand breaks promote the homologous recombination of specific gene locus points. The process focuses on the specific sequence of nucleic acid molecules targeted with endonucleases, such as chromosomes, and the endonucleases recognize and bind to sequences and induce double-strand breaks in nucleic acid molecules. Double-strand breaks are repaired by fallible non-homologous end joining (NHEJ) or by homologous recombination (HR). Exemplary "alteration" or "genetic alteration" techniques also include the introduction of gene expression modifying molecules, including but not limited to siRNA, shRNA, microRNA, antisense RNA, antisense oligonucleotides ASO (antisense oligonucleotides) or anti-miRNA oligonucleotides AMO (anti-miRNA oligonucleotides).
[0201] Those skilled in the art will appreciate that many different techniques can be used to engineer the pluripotent cells and pluripotent stem cells of the present invention to render them less immunogenic.
[0202] Typically, these techniques can be used alone or in combination. For example, CRISPR technology is used to reduce the expression of active B2M and / or CIITA proteins in modified cells, and viral technology (e.g., lentivirus) is used to knock in the CD68 gene. In addition, it will be understood by those skilled in the art that these genes can be manipulated in different orders using different techniques.
[0203] In some embodiments, the one or more changes contained in the low immunogenic pluripotent stem cells of the present invention can reduce the function of endogenous major histocompatibility class I antigen (MHC-I). In some embodiments, the one or more changes contained in the low immunogenic pluripotent stem cells of the present invention can reduce the function of endogenous major histocompatibility class II antigen (MHC-II). In some embodiments, the one or more changes contained in the low immunogenic pluripotent stem cells of the present invention can reduce the sensitivity to NK cell killing or macrophage killing. In some embodiments, the one or more changes contained in the low immunogenic pluripotent stem cells of the present invention can reduce the sensitivity to NK cell killing and macrophage killing.
[0204] In some embodiments, the hypoimmunogenic pluripotent stem cells of the present invention comprise one or more alterations that reduce the activity of endogenous B2M protein. In some embodiments, the hypoimmunogenic pluripotent stem cells of the present invention comprise one or more alterations that reduce the activity of endogenous CIITA protein. In some embodiments, the hypoimmunogenic pluripotent stem cells of the present invention comprise one or more alterations that increase the expression of CD68 protein.
[0205] In some embodiments, the hypoimmunogenic pluripotent stem cells of the present invention contain one or more alterations that inactivate both alleles of the endogenous B2M gene. In some embodiments, the hypoimmunogenic pluripotent stem cells of the present invention contain one or more alterations that inactivate both alleles of the endogenous CIITA gene. In some embodiments, the hypoimmunogenic pluripotent stem cells of the present invention contain one or more alterations that increase expression of the CD68 gene.
[0206] In some embodiments, the low immunogenicity pluripotent stem cells of the present invention comprise one or more changes that inhibit the expression of endogenous B2M protein. In some embodiments, the low immunogenicity pluripotent stem cells of the present invention comprise one or more changes that inhibit the expression of endogenous CIITA protein.
[0207] In some embodiments, the low immunogenic pluripotent stem cells of the present invention comprise one or more changes that interfere with the expression of endogenous B2M protein. In some embodiments, the low immunogenic pluripotent stem cells of the present invention comprise one or more changes that interfere with the expression of endogenous CIITA protein.
[0208] In some embodiments, the low immunogenicity pluripotent stem cells of the present invention comprise one or more changes that can reduce the expression of endogenous B2M protein. In some embodiments, the low immunogenicity pluripotent stem cells of the present invention comprise one or more changes that can reduce the expression of endogenous CIITA protein.
[0209] In some embodiments, the low immunogenic pluripotent stem cells of the present invention comprise one or more alterations that knock out endogenous B2M protein. In some embodiments, the low immunogenic pluripotent stem cells of the present invention comprise one or more alterations that knock out endogenous CIITA protein.
[0210] In one embodiment, the pluripotent stem cells are altered using Clustered Regularly Interspaced Short Palindromic Repeats / Cas ("CRISPR") technology known in the art to reduce the activity of endogenous B2M protein.
[0211] In one embodiment, the pluripotent stem cells are altered using Clustered Regularly Interspaced Short Palindromic Repeats / Cas ("CRISPR") technology known in the art to reduce the activity of endogenous CIITA protein.
[0212] In one embodiment, the pluripotent stem cells are altered to inactivate both alleles of the endogenous B2M gene using Clustered Regularly Interspaced Short Palindromic Repeats / Cas ("CRISPR") technology known in the art.
[0213] In one embodiment, the pluripotent stem cells are altered using Clustered Regularly Interspaced Short Palindromic Repeats / Cas ("CRISPR") technology known in the art to inactivate both alleles of the endogenous CIITA gene.
[0214] Determination of whether the test gene has been inactivated is known and described herein. In one embodiment, the determination is a Western blot of cell lysates probed with antibodies against B2M protein or CIITA protein. In another embodiment, reverse transcriptase polymerase chain reaction (RT-PCR) confirms the presence of inactivation changes.
[0215] In one embodiment, viral techniques known in the art can be used to induce increased expression of the CD68 gene in the hypoimmunogenic pluripotent stem cells. Such viral techniques include, but are not limited to, the use of retroviral vectors, lentiviral vectors, adenoviral vectors, and Sendai viral vectors. In some embodiments, a nucleic acid sequence encoding the CD68 protein is introduced into a selected site of the cell; the selected site of the cell is a safe harbor gene site such as AAVS1 or CCR5. As used herein, a "safe harbor gene site" refers to a site that can be used for safe gene knock-in and can ensure normal and stable expression of the transferred gene.
[0216] In a preferred embodiment, a lentiviral vector is used to induce increased expression of the CD68 gene in the low immunogenic pluripotent stem cells.
[0217] In one embodiment, the low immunogenic pluripotent stem cells are human pluripotent stem cells. In one embodiment, the B2M protein is a human B2M protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 1. In one embodiment, the CIITA protein is a human CIITA protein comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 2. In one embodiment, the CD68 protein is a human CD68 protein, which comprises the amino acid sequence shown in SEQ ID NO:3 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO:3.
[0218] In one embodiment, the low immunogenic pluripotent stem cells are cynomolgus monkey pluripotent stem cells. In one embodiment, the B2M protein is a cynomolgus monkey B2M protein comprising the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 9. In one embodiment, the CIITA protein is a cynomolgus monkey CIITA protein comprising the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 10. In one embodiment, the CD68 protein is a cynomolgus monkey CD68 protein, which comprises the amino acid sequence shown in SEQ ID NO:7 or an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO:7.
[0219] In some embodiments, the low immunogenicity pluripotent stem cells are low immunogenicity induced pluripotent stem cells (iPSCs).
[0220] In some embodiments, the low immunogenicity pluripotent stem cells are low immunogenicity human embryonic stem cells. In some embodiments, the human embryonic stem cells are commercial human embryonic stem cells (hESCs) (e.g., H1, H9). In some embodiments, the human embryonic stem cells are stem cells isolated or obtained from human embryos within 14 days of fertilization that have not undergone in vivo development.
[0221] In one embodiment, the hypoimmunogenic stem cells comprise:
[0222] reduced endogenous major histocompatibility class I antigen (MHC-I) function compared to parental pluripotent stem cells;
[0223] Reduced endogenous major histocompatibility class II antigen (MHC-II) function compared to the parental pluripotent stem cell; and
[0224] Reduced sensitivity to NK cell killing and / or macrophage killing compared to the parental pluripotent stem cell.
[0225] In one embodiment, the T cell response elicited by the low immunogenicity pluripotent stem cells is lower than the T cell response elicited by the parental pluripotent stem cells, and the parental pluripotent stem cells do not include the changes that reduce the activity of B2M and CIITA proteins and the changes that cause increased CD68 protein expression. In one embodiment, the T cell response is measured by real-time label-free dynamic cell analysis (RTCA) to measure the killing of T cells to the low immunogenicity pluripotent stem cells or parental pluripotent stem cells.
[0226] In one embodiment, the natural killer (NK) cell response triggered by the low immunogenic pluripotent stem cells is lower than the NK cell response triggered by the cloned DKO cells of B2M / CIITA double allele knockout, and the DKO cells include the changes that reduce the activity of B2M and CIITA proteins but do not include the changes that cause increased CD68 protein expression. In one embodiment, the NK cell response is measured by measuring the IFN-γ level of NK cells incubated in vitro with the low immunogenic pluripotent stem cells or DKO cells. In one embodiment, the NK cell response is measured by real-time label-free dynamic cell analysis (RTCA) to measure the lethality of NK cells to the low immunogenic pluripotent stem cells or DKO cells.
[0227] In one embodiment, the macrophage response elicited by the low immunogenicity pluripotent stem cells is lower than the macrophage response elicited by the parental pluripotent stem cells, and the parental pluripotent stem cells do not include the changes that reduce the activity of B2M and CIITA proteins and the changes that cause increased CD68 protein expression. In one embodiment, the macrophage response is measured by real-time label-free dynamic cell analysis (RTCA) to measure the killing of macrophages to the low immunogenicity pluripotent stem cells or parental pluripotent stem cells.
[0228] Method for producing low immunogenic pluripotent stem cells of the present invention
[0229] In a second aspect, the present invention also provides a method for producing the low immunogenic pluripotent stem cells of the present invention, the method comprising: reducing the endogenous major histocompatibility class I antigen (MHC-I) function in the pluripotent stem cells; reducing the endogenous major histocompatibility class II antigen (MHC-II) function in the pluripotent stem cells; and increasing the expression of a protein that reduces the sensitivity of the pluripotent stem cells to NK cell killing and / or macrophage killing, wherein the protein is CD68 protein.
[0230] In some embodiments, the low immunogenicity pluripotent stem cells are low immunogenicity induced pluripotent stem cells (iPSCs).
[0231] In some embodiments, the low immunogenicity pluripotent stem cells are low immunogenicity human embryonic stem cells. In some embodiments, the human embryonic stem cells are commercial human embryonic stem cells (hESCs) (e.g., H1, H9). In some embodiments, the human embryonic stem cells are stem cells isolated or obtained from human embryos within 14 days of fertilization that have not undergone in vivo development.
[0232] In some embodiments, the method comprises: reducing the activity of B2M protein in the pluripotent stem cells; reducing the activity of CIITA protein in the pluripotent stem cells; and increasing the expression of CD68 protein in the pluripotent stem cells.
[0233] In one embodiment, the method comprises: eliminating the activity of both alleles of the B2M gene in the pluripotent stem cells; eliminating the activity of both alleles of the CIITA gene in the pluripotent stem cells; and increasing the expression of the CD68 gene in the pluripotent stem cells.
[0234] In some embodiments, the activity of the B2M protein in the pluripotent stem cells can be reduced by the technology of “changing” or “genetic change” as described above. In some embodiments, the activity of the CIITA protein in the pluripotent stem cells can be reduced by the technology of “changing” or “genetic change” as described above. The technology, for example, introduces gene expression modification molecules, clustered regularly interspaced short palindromic repeats (CRISPR) technology, transcription activator-like effector nuclease (TALEN) technology, zinc finger nuclease (ZFN) technology or homologous recombination technology. In a preferred embodiment, the gene expression modification molecule comprises siRNA, shRNA, microRNA, antisense RNA, antisense oligonucleotides ASO (antisense oligonucleotides) or anti-miRNA oligonucleotides AMO (Anti-miRNA oligonucleotides).
[0235] In some embodiments, the CRISPR / Cas system includes a Cas protein or a nucleic acid sequence encoding a Cas protein and at least one to two ribonucleic acids (e.g., gRNA), which can guide the Cas protein to a target motif of a target polynucleotide sequence and hybridize to the target motif. In some embodiments, the CRISPR / Cas system includes a Cas protein or a nucleic acid sequence encoding a Cas protein and a single ribonucleic acid or at least one ribonucleic acid (e.g., gRNA) pair, which can guide the Cas protein to a target motif of a target polynucleotide sequence and hybridize to the target motif.
[0236] In some embodiments, the Cas protein comprises one or more amino acid substitutions or modifications. In some embodiments, one or more amino acid substitutions comprise conservative amino acid substitutions. In some cases, substitutions and / or modifications can prevent or reduce proteolytic degradation and / or prolong the half-life of the polypeptide in the cell. In some embodiments, the Cas protein may comprise peptide bond replacements (e.g., urea, thiourea, carbamate, sulfonylurea, etc.). In some embodiments, the Cas protein may comprise naturally occurring amino acids. In some embodiments, the Cas protein may comprise optional amino acids (e.g., D-amino acids, β-amino acids, homocysteine, phosphoserine, etc.). In some embodiments, the Cas protein may comprise modifications to include portions (e.g., pegylation, glycosylation, lipidation, acetylation, end-capping, etc.).
[0237] In some embodiments, the Cas protein comprises a core Cas protein. Exemplary Cas core proteins include but are not limited to Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, and Cas9. In some embodiments, the Cas protein comprises a Cas protein of the Escherichia coli (E. coli) subtype (also referred to as CASS2). Exemplary Cas proteins of the E. coli subtype include but are not limited to Cse1, Cse2, Cse3, Cse4, and Cas5e. In some embodiments, the Cas protein comprises a Cas protein of the Ypest subtype (also referred to as CASS3). Exemplary Cas proteins of the Ypest subtype include but are not limited to Csy1, Csy2, Csy3, and Csy4. In some embodiments, the Cas protein comprises a Cas protein of the Nmeni subtype (also referred to as CASS4). Exemplary Cas proteins of the Nmeni subtype include but are not limited to Csn1 and Csn2. In some embodiments, the Cas protein comprises a Cas protein of the Dvulg subtype (also referred to as CASS1). Exemplary Cas proteins of the Dvulg subtype include but are not limited to Csd1, Csd2, and Cas5d. In some embodiments, the Cas protein comprises a Cas protein of the Tneap subtype (also known as CASS7). Exemplary Cas proteins of the Tneap subtype include but are not limited to Cst1, Cst2, and Cas5t. In some embodiments, the Cas protein comprises a Cas protein of the Hmari subtype. Exemplary Cas proteins of the Hmari subtype include but are not limited to Csh1, Csh2, and Cas5h. In some embodiments, the Cas protein comprises a Cas protein of the Apern subtype (also known as CASS5). Exemplary Cas proteins of the Apern subtype include but are not limited to Csa1, Csa2, Csa3, Csa4, Csa5, and Cas5a. In some embodiments, the Cas protein comprises a Cas protein of the Mtube subtype (also known as CASS6). Exemplary Cas proteins of the Mtube subtype include but are not limited to Csm1, Csm2, Csm3, Csm4, and Csm5. In some embodiments, the Cas protein comprises a RAMP-type Cas protein. Exemplary RAMP-type Cas proteins include but are not limited to Cmr1, Cmr2, Cmr3, Cmr4, Cmr5, and Cmr6.
[0238] In some embodiments, the Cas protein is Streptococcus pyogenes Cas9 protein or a functional portion thereof. In some embodiments, the Cas protein is Staphylococcus aureus Cas9 protein or a functional portion thereof. In some embodiments, the Cas protein is Streptococcus thermophilus Cas9 protein or a functional portion thereof. In some embodiments, the Cas protein is Neisseria meningitides Cas9 protein or a functional portion thereof. In some embodiments, the Cas protein is Treponema denticola Cas9 protein or a functional portion thereof. In some embodiments, the Cas protein is Cas9 protein from any bacterial species or a functional portion thereof. Cas9 protein is a member of the Type II CRISPR system, which typically includes a trans-encoded small RNA (tracrRNA), an endogenous ribonuclease 3 (rnc), and a Cas protein. The Cas9 protein (also known as CRISPR-associated endonuclease Cas9 / Csn1) is a polypeptide containing 1368 amino acids.
[0239] In one embodiment, the activity of B2M protein in the pluripotent stem cells is reduced by clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 gene editing technology.
[0240] In one embodiment, the activities of both alleles of the B2M gene in the pluripotent stem cells are eliminated by clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 gene editing technology.
[0241] In one embodiment, the activity of CIITA protein in the pluripotent stem cells is reduced by clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 gene editing technology.
[0242] In one embodiment, the activity of both alleles of the CIITA gene in the pluripotent stem cells is eliminated by clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 gene editing technology.
[0243] In one embodiment, the expression of CD68 protein is increased by modification of the endogenous locus. In some embodiments, the endogenous locus is modified by the technology of "alteration" or "genetic alteration" as described above. The technology, for example, gene knock-in, clustered regularly interspaced short palindromic repeats (CRISPR) technology, transcription activator-like effector nuclease (TALEN) technology, zinc finger nuclease (ZFN) technology or homologous recombination technology.
[0244] In one embodiment, the expression of CD68 protein is increased by expression of a transgene. Transgenic expression techniques known in the art can be used to increase the expression of CD68 protein, including but not limited to viral technology, Piggybac transposon technology, and Sleeping Beauty transposon technology.
[0245] In this article, known recombinant techniques can be used to produce expression constructs as described herein. In certain embodiments, the nucleic acid sequence encoding the target protein can be operably connected to one or more regulatory nucleotide sequences in the expression construct. The regulatory nucleotide sequence is generally suitable for host cells and subjects to be treated. Various types of suitable expression vectors and suitable regulatory sequences are known in the art for use in a variety of host cells. Generally, one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader sequences or signal sequences, ribosome binding sites, transcription start and stop sequences, translation start and stop sequences, and enhancer or activator sequences. The expression constructs used herein can use constitutive or inducible promoters known in the art. The promoter can be a naturally occurring promoter, or a hybrid promoter combining elements of more than one promoter. The expression construct can be present in the cell on an episome (e.g., a plasmid), or the expression construct can be inserted into a chromosome. In a specific embodiment, the expression vector includes a selectable marker gene to allow selection of transformed host cells. Some embodiments include an expression vector comprising a nucleotide sequence encoding the target protein operably connected to at least one regulatory sequence. Regulatory sequences used herein include promoters, enhancers, and other expression control elements. In certain embodiments, the expression vector is designed to select the host cell to be transformed, the desired protein to be expressed, the copy number of the vector, the ability to control the copy number, or the expression of any other protein encoded by the vector, such as an antibiotic marker. In some embodiments, the promoter is the EF1a promoter.
[0246] Viral technology can be used to cause increased expression of the CD68 gene in the low immunogenic pluripotent stem cells. The viral technology includes but is not limited to the use of retroviral vectors, lentiviral vectors, adenoviral vectors and Sendai virus vectors.
[0247] In a preferred embodiment, a nucleic acid sequence encoding CD68 protein is synthesized and constructed into a lentiviral vector, and then at least one copy of the CD68 gene under the control of a promoter is introduced into the pluripotent stem cells via the lentiviral vector to increase the expression of CD68 protein.
[0248] In one embodiment, a nucleic acid sequence encoding the CD68 protein is introduced into a selected site in the genome of the pluripotent stem cell. In a preferred embodiment, the selected site is a safe harbor gene locus such as AAVS1 or CCR5. As used herein, a "safe harbor gene locus" refers to a site that can be used for safe gene knock-in and ensures normal and stable expression of the transferred gene.
[0249] In one embodiment, the CD68 protein is human CD68 protein.
[0250] In one embodiment, the nucleic acid sequence encoding the CD68 protein comprises the nucleic acid sequence shown in SEQ ID NO:4 or a nucleic acid sequence that is at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in SEQ ID NO:4.
[0251] In one embodiment, the CD68 protein is cynomolgus monkey CD68 protein.
[0252] In one embodiment, the nucleic acid sequence encoding the CD68 protein comprises the nucleic acid sequence shown in SEQ ID NO:8 or a nucleic acid sequence that is at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in SEQ ID NO:8.
[0253] Kit for preparing low-immunogenic cardiomyocytes
[0254] In a fourth aspect, the present invention provides a kit for preparing low immunogenic cardiomyocytes, the kit comprising the low immunogenic pluripotent stem cells of the first aspect or the low immunogenic pluripotent stem cells prepared by the method of the second aspect, a first culture medium, a second culture medium and a third culture medium; the first culture medium is a basal culture medium containing a GSK-3 inhibitor; and the third culture medium is a basal culture medium containing a Wnt inhibitor.
[0255] In one embodiment, the first culture medium is a basal culture medium comprising a GSK-3 inhibitor.
[0256] In one embodiment, the first culture medium is a basal medium comprising a GSK-3 inhibitor and B27 supplement without insulin.
[0257] In one embodiment, the GSK-3 inhibitor is selected from CHIR99021, GSK3β inhibitor IX, SB216763, GSK3β inhibitor VII, L803-mts, 6-bromo-indirubin-3'-oxime, TWS119, AZD2858, AR-A014418, TDZD-8, LY2090314, 2-D08, IM-12, 1-Azakenpaullone, and Indirubin.
[0258] In a preferred embodiment, the GSK-3 inhibitor comprises or is CHIR99021.
[0259] In one embodiment, the concentration of the GSK-3 inhibitor is 0.5 mM to 10 μM, preferably 6 mM.
[0260] In one embodiment, the concentration of the GSK-3 inhibitor CHIR99021 is 0.5 μM-10 μM, preferably 6 μM.
[0261] In one embodiment, the basal culture medium of the first culture medium is selected from IMDM (Iscove's Modified Dulbecco's Medium) medium, Eagle's Basal Medium (BME) medium, MEM medium, DMEM medium, Ham's F-12 medium, RPMI1640 medium, Fischer's medium, E8 medium, mTESR medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF medium, StemMACS iPS Brew medium, Stem-Partner ACF medium, TeSR-AOF medium, TeSR2 medium, StemFit complete medium, RPMI1640 medium, and mTESR1 medium.
[0262] In a preferred embodiment, the basal medium of the first culture medium comprises or is PRMI1640 basal medium.
[0263] In one embodiment, the concentration of the insulin-free B27 supplement in the basal medium of the first culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0264] In one embodiment, the third culture medium is a basal medium comprising a Wnt inhibitor.
[0265] In one embodiment, the third culture medium is a basal medium comprising a Wnt inhibitor and B27 supplement without insulin.
[0266] In one embodiment, the Wnt inhibitor comprises at least 1, 2, 3, or 4 selected from the group consisting of IWR-1, IWP-2, IWP-4, and C59.
[0267] In one embodiment, the Wnt inhibitor comprises at least one selected from IWR-1, IWP-2, IWP-4, and C59.
[0268] In a preferred embodiment, the Wnt inhibitor comprises or is IWR-1.
[0269] In one embodiment, the concentration of the Wnt inhibitor is 0.5 μM to 20 μM, preferably 2 μM.
[0270] In one embodiment, the concentration of the Wnt inhibitor IWR-1 is 0.5 μM to 20 μM, preferably 2 μM.
[0271] In one embodiment, the basal culture medium of the third culture medium is selected from IMDM (Iscove's Modified Dulbecco's Medium) medium, Eagle's Basal Medium (BME) medium, MEM medium, DMEM medium, Ham's F-12 medium, RPMI1640 medium, Fischer's medium, E8 medium, mTESR medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF medium, StemMACS iPS Brew medium, Stem-Partner ACF medium, TeSR-AOF medium, TeSR2 medium, StemFit complete medium, RPMI1640 medium, and mTESR1 medium.
[0272] In a preferred embodiment, the basal medium of the third culture medium comprises or is PRMI1640 basal medium.
[0273] In one embodiment, the concentration of the insulin-free B27 supplement in the basal medium of the third culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0274] In one embodiment, the second culture medium is a basal medium comprising B27 supplement without insulin.
[0275] In one embodiment, the basal medium of the second culture medium is selected from IMDM (Iscove's Modified Dulbecco's Medium) medium, Eagle's Basal Medium (BME) medium, MEM medium, DMEM medium, Ham's F-12 medium, RPMI1640 medium, Fischer's medium, E8 medium, mTESR medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF medium, StemMACS iPS Brew medium, Stem-Partner ACF medium, TeSR-AOF medium, TeSR2 medium, StemFit complete medium, RPMI1640 medium, and mTESR1 medium.
[0276] In a preferred embodiment, the basal medium of the second culture medium comprises or is PRMI1640 basal medium.
[0277] In one embodiment, the concentration of the insulin-free B27 supplement in the basal medium of the second culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0278] In one embodiment, the first culture medium is a basal medium comprising a GSK-3 inhibitor and B27 supplement without insulin; and the third culture medium is a basal medium comprising a Wnt inhibitor and B27 supplement without insulin.
[0279] In one embodiment, the first culture medium is PRMI1640 basal medium comprising a GSK-3 inhibitor and B27 supplement without insulin; and the third culture medium is PRMI1640 basal medium comprising a Wnt inhibitor and B27 supplement without insulin.
[0280] In one embodiment, the kit comprises a first culture medium, a second culture medium, and a third culture medium; the first culture medium is a basal culture medium comprising a GSK-3 inhibitor and a B27 supplement without insulin; the second culture medium is a basal culture medium comprising a B27 supplement without insulin; and the third culture medium is a basal culture medium comprising a Wnt inhibitor and a B27 supplement without insulin.
[0281] In one embodiment, the kit comprises a first culture medium, a second culture medium, and a third culture medium; the first culture medium is PRMI1640 basal medium comprising a GSK-3 inhibitor and a B27 supplement without insulin; the second culture medium is PRMI1640 basal medium comprising a B27 supplement without insulin; and the third culture medium is PRMI1640 basal medium comprising a Wnt inhibitor and a B27 supplement without insulin.
[0282] In one embodiment, the kit further comprises a fourth culture medium.
[0283] In one embodiment, the fourth culture medium is a basal medium comprising a B27 supplement containing insulin.
[0284] In one embodiment, the basal medium of the fourth culture medium is selected from IMDM (Iscove's Modified Dulbecco's Medium) medium, Eagle's Basal Medium (BME) medium, MEM medium, DMEM medium, Ham's F-12 medium, RPMI1640 medium, Fischer's medium, E8 medium, mTESR medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF medium, StemMACS iPS Brew medium, Stem-Partner ACF medium, TeSR-AOF medium, TeSR2 medium, StemFit complete medium, RPMI1640 medium, and mTESR1 medium.
[0285] In a preferred embodiment, the basal medium of the fourth culture medium comprises or is PRMI1640 basal medium.
[0286] In one embodiment, the concentration of the B27 supplement containing insulin in the basal medium of the fourth culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0287] In one embodiment, the kit further comprises a fifth culture medium.
[0288] In one embodiment, the fifth culture medium is a basal medium comprising a ROCK inhibitor.
[0289] In a preferred embodiment, the ROCK inhibitor comprises or is Y-27632.
[0290] In one embodiment, the basal medium of the fifth culture medium is selected from IMDM (Iscove's Modified Dulbecco's Medium) medium, Eagle's Basal Medium (BME) medium, MEM medium, DMEM medium, Ham's F-12 medium, RPMI1640 medium, Fischer's medium, E8 medium, mTESR medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF medium, StemMACS iPS Brew medium, Stem-Partner ACF medium, TeSR-AOF medium, TeSR2 medium, StemFit complete medium, RPMI1640 medium, and mTESR1 medium.
[0291] In a preferred embodiment, the basal medium of the fifth culture medium comprises or is mTeSR1 basal medium.
[0292] In one embodiment, the kit further comprises a sixth culture medium.
[0293] In one embodiment, the sixth culture medium is a basal medium.
[0294] In one embodiment, the basal medium of the sixth culture medium is selected from IMDM (Iscove's Modified Dulbecco's Medium) medium, Eagle's Basal Medium (BME) medium, MEM medium, DMEM medium, Ham's F-12 medium, RPMI1640 medium, Fischer's medium, E8 medium, mTESR medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF medium, StemMACS iPS Brew medium, Stem-Partner ACF medium, TeSR-AOF medium, TeSR2 medium, StemFit complete medium RPMI1640 medium, and mTESR1 medium.
[0295] In one embodiment, the basal medium of the sixth culture medium comprises or is mTeSR1 basal medium.
[0296] In one embodiment, the kit further comprises a fourth culture medium, which is a basal culture medium containing a B27 supplement containing insulin; the kit further comprises a fifth culture medium, which is a basal culture medium containing a ROCK inhibitor; and the kit further comprises a sixth culture medium, which is a basal culture medium.
[0297] In one embodiment, the kit further comprises a fourth culture medium, which is a PRMI1640 basal culture medium containing a B27 supplement containing insulin; the kit further comprises a fifth culture medium, which is an mTeSR1 basal culture medium containing a ROCK inhibitor Y-27632; and the kit further comprises a sixth culture medium, which comprises or is an mTeSR1 basal culture medium.
[0298] In one embodiment, the kit comprises a first culture medium, a second culture medium, a third culture medium, a fourth culture medium, a fifth culture medium, and a sixth culture medium; the first culture medium is a basal culture medium comprising a GSK-3 inhibitor and a B27 additive without insulin; the second culture medium is a basal culture medium comprising a B27 additive without insulin; the third culture medium is a basal culture medium comprising a Wnt inhibitor and a B27 additive without insulin; the fourth culture medium is a basal culture medium comprising a B27 additive with insulin; the fifth culture medium is a basal culture medium comprising a ROCK inhibitor; and the sixth culture medium is a basal culture medium.
[0299] In one embodiment, the kit comprises a first culture medium, a second culture medium, a third culture medium, a fourth culture medium, a fifth culture medium, and a sixth culture medium; the first culture medium is PRMI1640 basal culture medium comprising a GSK-3 inhibitor and a B27 supplement without insulin; the second culture medium is PRMI1640 basal culture medium comprising a B27 supplement without insulin; the third culture medium is PRMI1640 basal culture medium comprising a Wnt inhibitor and a B27 supplement without insulin; the fourth culture medium is PRMI1640 basal culture medium comprising a B27 supplement with insulin; the fifth culture medium is mTeSR1 basal culture medium comprising a ROCK inhibitor Y-27632; and the sixth culture medium comprises or is mTeSR1 basal culture medium.
[0300] Method for preparing low immunogenic cardiomyocytes
[0301] In a fifth aspect, the present invention provides a method for preparing low immunogenic cardiomyocytes, the method comprising using the kit of the fourth aspect.
[0302] In one embodiment, the method comprises:
[0303] Cultivating the low immunogenicity pluripotent stem cells of the first aspect or the low immunogenicity pluripotent stem cells prepared by the method of the second aspect in a first culture medium;
[0304] The first culture medium was replaced with the second culture medium, and the cells were continued to be cultured;
[0305] The second culture medium was replaced with the third culture medium, and the cells were continued to be cultured;
[0306] replacing the third culture medium with the second culture medium, and continuing to culture the cells; and
[0307] Obtain differentiated low-immunogenic cardiomyocytes.
[0308] In one embodiment, the hypoimmunogenic pluripotent stem cells are cultured in the first culture medium for 2 days. In one embodiment, the first culture medium is exchanged for the second culture medium, and the cells are cultured for another day. In one embodiment, the second culture medium is exchanged for the third culture medium, and the cells are cultured for another 2 days. In one embodiment, the third culture medium is exchanged for the second culture medium, and the cells are cultured for another 10 days.
[0309] In one embodiment, the method comprises:
[0310] culturing the low immunogenicity pluripotent stem cells in the first culture medium for 2 days;
[0311] The first culture medium was replaced with the second culture medium, and the cells were cultured for another day;
[0312] The second culture medium was replaced with the third culture medium, and the cells were cultured for another 2 days;
[0313] replacing the third culture medium with the second culture medium, and continuing to culture the cells for 10 days; and
[0314] Obtain differentiated low-immunogenic cardiomyocytes.
[0315] In one embodiment, the method comprises:
[0316] adding a GSK-3 inhibitor to the second culture medium, and culturing the low immunogenicity pluripotent stem cells in the second culture medium supplemented with the GSK-3 inhibitor;
[0317] The second culture medium supplemented with the GSK-3 inhibitor was replaced with the second culture medium, and the cells were continued to be cultured;
[0318] adding a Wnt inhibitor to the second culture medium, and continuing to culture the cells in the second culture medium supplemented with the Wnt inhibitor;
[0319] replacing the second culture medium supplemented with the Wnt inhibitor with the second culture medium, and continuing to culture the cells; and
[0320] Obtain differentiated low-immunogenic cardiomyocytes.
[0321] In one embodiment, the second culture medium supplemented with the GSK-3 inhibitor is the first culture medium. In one embodiment, the second culture medium supplemented with the Wnt inhibitor is the third culture medium.
[0322] In one embodiment, the GSK-3 inhibitor is selected from CHIR99021, GSK3β inhibitor IX, SB216763, GSK3β inhibitor VII, L803-mts, 6-bromo-indirubin-3'-oxime, TWS119, AZD2858, AR-A014418, TDZD-8, LY2090314, 2-D08, IM-12, 1-Azakenpaullone, and Indirubin.
[0323] In a preferred embodiment, the GSK-3 inhibitor comprises or is CHIR99021.
[0324] In one embodiment, the concentration of the GSK-3 inhibitor is 0.5 μM to 10 μM, preferably 6 μM.
[0325] In one embodiment, the concentration of the GSK-3 inhibitor CHIR99021 is 0.5 μM-10 μM, preferably 6 μM.
[0326] In one embodiment, the Wnt inhibitor comprises at least 1, 2, 3, or 4 selected from the group consisting of IWR-1, IWP-2, IWP-4, and C59.
[0327] In one embodiment, the Wnt inhibitor comprises at least one selected from IWR-1, IWP-2, IWP-4, and C59.
[0328] In a preferred embodiment, the Wnt inhibitor comprises or is IWR-1.
[0329] In one embodiment, the concentration of the Wnt inhibitor is 0.5 μM to 20 μM, preferably 2 μM.
[0330] In one embodiment, the concentration of the Wnt inhibitor IWR-1 is 0.5 μM to 20 μM, preferably 2 μM.
[0331] In one embodiment, the method comprises:
[0332] adding CHIR99021 to the second culture medium, and culturing the low immunogenicity pluripotent stem cells in the second culture medium supplemented with CHIR99021;
[0333] The second culture medium supplemented with CHIR99021 was replaced with the second culture medium and the cells were continued to be cultured;
[0334] adding IWR-1 to the second culture medium, and continuing to culture the cells in the second culture medium supplemented with IWR-1;
[0335] replacing the second culture medium supplemented with IWR-1 with the second culture medium and continuing to culture the cells; and
[0336] Obtain differentiated low-immunogenic cardiomyocytes.
[0337] In one embodiment, the second culture medium supplemented with CHIR99021 is the first culture medium. In one embodiment, the second culture medium supplemented with IWR-1 is the third culture medium.
[0338] In one embodiment, a GSK-3 inhibitor is added to the second culture medium, and the hypoimmunogenic pluripotent stem cells are cultured in the second culture medium supplemented with the GSK-3 inhibitor for 2 days. In one embodiment, the second culture medium supplemented with the GSK-3 inhibitor is replaced with the second culture medium, and the cells are cultured for another day. In one embodiment, a Wnt inhibitor is added to the second culture medium, and the cells are cultured in the second culture medium supplemented with the Wnt inhibitor for another 2 days. In one embodiment, the second culture medium supplemented with the Wnt inhibitor is replaced with the second culture medium, and the cells are cultured for another 10 days.
[0339] In one embodiment, the method comprises:
[0340] adding a GSK-3 inhibitor to the second culture medium, and culturing the low immunogenicity pluripotent stem cells in the second culture medium supplemented with the GSK-3 inhibitor for 2 days;
[0341] The second culture medium supplemented with the GSK-3 inhibitor was replaced with the second culture medium, and the cells were cultured for another day;
[0342] adding a Wnt inhibitor to the second culture medium, and continuing to culture the cells in the second culture medium supplemented with the Wnt inhibitor for 2 days;
[0343] replacing the second culture medium supplemented with the Wnt inhibitor with the second culture medium, and continuing to culture the cells for 10 days; and
[0344] Obtain differentiated low-immunogenic cardiomyocytes.
[0345] In one embodiment, the method comprises:
[0346] adding CHIR99021 to the second culture medium, and culturing the low immunogenicity pluripotent stem cells in the second culture medium supplemented with CHIR99021 for 2 days;
[0347] The second culture medium supplemented with CHIR99021 was replaced with the second culture medium, and the cells were cultured for another day;
[0348] IWR-1 was added to the second culture medium, and the cells were cultured in the second culture medium supplemented with IWR-1 for another 2 days;
[0349] replacing the second culture medium supplemented with IWR-1 with the second culture medium, and continuing to culture the cells for 10 days; and
[0350] Obtain differentiated low-immunogenic cardiomyocytes.
[0351] The above method is a method for inducing low-immunogenicity pluripotent stem cells to differentiate into low-immunogenicity cardiomyocytes.
[0352] In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in a fifth culture medium before culturing the reduced immunogenicity pluripotent stem cells in the first culture medium. In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in the fifth culture medium before culturing the reduced immunogenicity pluripotent stem cells in the second culture medium supplemented with a GSK-3 inhibitor.
[0353] In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in a sixth culture medium before culturing the reduced immunogenicity pluripotent stem cells in the first culture medium. In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in the sixth culture medium before culturing the reduced immunogenicity pluripotent stem cells in the second culture medium supplemented with a GSK-3 inhibitor.
[0354] In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in a fifth culture medium and culturing the reduced immunogenicity pluripotent stem cells in a sixth culture medium before culturing the reduced immunogenicity pluripotent stem cells in the first culture medium. In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in the fifth culture medium and culturing the reduced immunogenicity pluripotent stem cells in the sixth culture medium before culturing the reduced immunogenicity pluripotent stem cells in the second culture medium supplemented with a GSK-3 inhibitor.
[0355] In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in a fifth culture medium before culturing the reduced immunogenicity pluripotent stem cells in the first culture medium, and then culturing the reduced immunogenicity pluripotent stem cells in a sixth culture medium. In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in the fifth culture medium before culturing the reduced immunogenicity pluripotent stem cells in the second culture medium supplemented with a GSK-3 inhibitor, and then culturing the reduced immunogenicity pluripotent stem cells in the sixth culture medium.
[0356] In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in a fifth culture medium for one day, and then culturing the reduced immunogenicity pluripotent stem cells in a sixth culture medium for one day, before culturing the reduced immunogenicity pluripotent stem cells in the first culture medium. In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in the fifth culture medium for one day, and then culturing the reduced immunogenicity pluripotent stem cells in the sixth culture medium for one day, before culturing the reduced immunogenicity pluripotent stem cells in the second culture medium supplemented with a GSK-3 inhibitor.
[0357] In one embodiment, the method comprises, when the low immunogenicity pluripotent stem cells cultured in the sixth culture medium grow to 85-98% confluence, replacing the sixth culture medium with the first culture medium for inducing differentiation. In one embodiment, the method comprises, when the low immunogenicity pluripotent stem cells cultured in the sixth culture medium grow to 85-98% confluence, replacing the sixth culture medium with the second culture medium supplemented with a GSK-3 inhibitor for inducing differentiation.
[0358] Culturing the low immunogenicity pluripotent stem cells in the fifth culture medium and / or culturing the low immunogenicity pluripotent stem cells in the sixth culture medium is a method of culturing the low immunogenicity pluripotent stem cells to a cell confluence required for differentiation before inducing differentiation. In one embodiment, the cell confluence is 85-98%, including 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and preferably 95% confluence.
[0359] In one embodiment, the method further comprises culturing and maintaining the differentiated reduced immunogenic cardiomyocytes in a fourth culture medium after obtaining the differentiated reduced immunogenic cardiomyocytes.
[0360] In one embodiment, the method comprises re-plating after obtaining the differentiated reduced immunogenic cardiomyocytes, and then culturing and maintaining the differentiated reduced immunogenic cardiomyocytes in a fourth culture medium.
[0361] Culturing and maintaining the differentiated low immunogenic cardiomyocytes in a fourth culture medium is a method for maintaining and culturing the differentiated low immunogenic cardiomyocytes.
[0362] In one embodiment, the method comprises:
[0363] culturing the low immunogenic pluripotent stem cells in a fifth culture medium;
[0364] The fifth culture medium is replaced with the sixth culture medium, and the low immunogenic pluripotent stem cells are continued to be cultured;
[0365] replacing the sixth culture medium with the first culture medium, culturing the low-immunogenicity pluripotent stem cells in the first culture medium to begin inducing differentiation into cardiomyocytes;
[0366] The first culture medium was replaced with the second culture medium, and the cells were continued to be cultured;
[0367] The second culture medium was replaced with the third culture medium, and the cells were continued to be cultured;
[0368] The third culture medium was replaced with the second culture medium, and the cells were continued to be cultured;
[0369] Obtain differentiated low-immunogenic cardiomyocytes;
[0370] The differentiated low immunogenic cardiomyocytes were cultured and maintained in the fourth culture medium.
[0371] In one embodiment, the method comprises:
[0372] culturing the low immunogenic pluripotent stem cells in a fifth culture medium;
[0373] The fifth culture medium is replaced with the sixth culture medium, and the low immunogenic pluripotent stem cells are continued to be cultured;
[0374] adding a GSK-3 inhibitor to the second culture medium, replacing the sixth culture medium with the second culture medium supplemented with the GSK-3 inhibitor, and culturing the low-immunogenicity pluripotent stem cells in the second culture medium supplemented with the GSK-3 inhibitor to initiate induction of differentiation into cardiomyocytes;
[0375] The second culture medium supplemented with the GSK-3 inhibitor was replaced with the second culture medium, and the cells were continued to be cultured;
[0376] adding a Wnt inhibitor to the second culture medium, and continuing to culture the cells in the second culture medium supplemented with the Wnt inhibitor;
[0377] The second culture medium supplemented with the Wnt inhibitor was replaced with the second culture medium, and the cells were continued to be cultured;
[0378] Obtain differentiated low-immunogenic cardiomyocytes;
[0379] The differentiated low immunogenic cardiomyocytes were cultured and maintained in the fourth culture medium.
[0380] In one embodiment, the method comprises:
[0381] culturing the low immunogenic pluripotent stem cells in a fifth culture medium;
[0382] The fifth culture medium is replaced with the sixth culture medium, and the low immunogenic pluripotent stem cells are continued to be cultured;
[0383] adding CHIR99021 to the second culture medium, replacing the sixth culture medium with the second culture medium supplemented with CHIR99021, and culturing the low immunogenicity pluripotent stem cells in the second culture medium supplemented with CHIR99021 to initiate induction of differentiation into cardiomyocytes;
[0384] The second culture medium supplemented with CHIR99021 was replaced with the second culture medium and the cells were continued to be cultured;
[0385] adding IWR-1 to the second culture medium, and continuing to culture the cells in the second culture medium supplemented with IWR-1;
[0386] The second culture medium supplemented with IWR-1 was replaced with the second culture medium and the cells were continued to be cultured;
[0387] Obtain differentiated low-immunogenic cardiomyocytes;
[0388] The differentiated low immunogenic cardiomyocytes were cultured and maintained in the fourth culture medium.
[0389] In one embodiment, the hypoimmunogenic pluripotent stem cells are cultured in the fifth culture medium for one day. In one embodiment, the fifth culture medium is replaced with the sixth culture medium, and the hypoimmunogenic pluripotent stem cells are cultured for another day. In one embodiment, the differentiated hypoimmunogenic cardiomyocytes are cultured and maintained in the fourth culture medium for 15 days.
[0390] In one embodiment, the method comprises:
[0391] culturing the low immunogenicity pluripotent stem cells in the fifth culture medium for 1 day;
[0392] The fifth culture medium was replaced with the sixth culture medium, and the low immunogenicity pluripotent stem cells were cultured for another day;
[0393] replacing the sixth culture medium with the first culture medium, and culturing the low-immunogenicity pluripotent stem cells in the first culture medium for 2 days to begin inducing differentiation into cardiomyocytes;
[0394] The first culture medium was replaced with the second culture medium, and the cells were cultured for another day;
[0395] The second culture medium was replaced with the third culture medium, and the cells were cultured for another 2 days;
[0396] The third culture medium was replaced with the second culture medium, and the cells were cultured for another 10 days;
[0397] Obtain differentiated low-immunogenic cardiomyocytes;
[0398] The differentiated low immunogenic cardiomyocytes were cultured and maintained in the fourth culture medium for 15 days.
[0399] In one embodiment, the method comprises:
[0400] culturing the low immunogenicity pluripotent stem cells in the fifth culture medium for 1 day;
[0401] The fifth culture medium was replaced with the sixth culture medium, and the low immunogenicity pluripotent stem cells were cultured for another day;
[0402] adding a GSK-3 inhibitor to the second culture medium, replacing the sixth culture medium with the second culture medium supplemented with the GSK-3 inhibitor, and culturing the low immunogenicity pluripotent stem cells in the second culture medium supplemented with the GSK-3 inhibitor for 2 days to initiate induction of differentiation into cardiomyocytes;
[0403] The second culture medium supplemented with the GSK-3 inhibitor was replaced with the second culture medium, and the cells were cultured for another day;
[0404] adding a Wnt inhibitor to the second culture medium, and continuing to culture the cells in the second culture medium supplemented with the Wnt inhibitor for 2 days;
[0405] The second culture medium supplemented with Wnt inhibitor was replaced with the second culture medium, and the cells were cultured for another 10 days;
[0406] Obtain differentiated low-immunogenic cardiomyocytes;
[0407] The differentiated low immunogenic cardiomyocytes were cultured and maintained in the fourth culture medium for 15 days.
[0408] In one embodiment, the method comprises:
[0409] culturing the low immunogenicity pluripotent stem cells in the fifth culture medium for 1 day;
[0410] The fifth culture medium was replaced with the sixth culture medium, and the low immunogenicity pluripotent stem cells were cultured for another day;
[0411] adding CHIR99021 to the second culture medium, replacing the sixth culture medium with the second culture medium supplemented with CHIR99021, and culturing the low immunogenicity pluripotent stem cells in the second culture medium supplemented with CHIR99021 for 2 days to initiate induction of differentiation into cardiomyocytes;
[0412] The second culture medium supplemented with CHIR99021 was replaced with the second culture medium, and the cells were cultured for another day;
[0413] IWR-1 was added to the second culture medium, and the cells were cultured in the second culture medium supplemented with IWR-1 for another 2 days;
[0414] The second culture medium supplemented with IWR-1 was replaced with the second culture medium, and the cells were cultured for another 10 days;
[0415] Obtain differentiated low-immunogenic cardiomyocytes;
[0416] The differentiated low immunogenic cardiomyocytes were cultured and maintained in the fourth culture medium for 15 days.
[0417] In a sixth aspect, the present invention provides a method for preparing low immunogenic cardiomyocytes, the method comprising:
[0418] adding a GSK-3 inhibitor to a cardiomyocyte differentiation medium, and culturing the low immunogenicity pluripotent stem cells of the first aspect or the low immunogenicity pluripotent stem cells prepared by the method of the second aspect in the cardiomyocyte differentiation medium supplemented with the GSK-3 inhibitor;
[0419] The cardiomyocyte differentiation medium supplemented with GSK-3 inhibitor was replaced with cardiomyocyte differentiation medium and the cells were continued to be cultured;
[0420] adding a Wnt inhibitor to the cardiomyocyte differentiation medium and continuing to culture the cells in the cardiomyocyte differentiation medium supplemented with the Wnt inhibitor;
[0421] replacing the cardiomyocyte differentiation medium supplemented with Wnt inhibitors with cardiomyocyte differentiation medium and continuing to culture the cells; and
[0422] Obtain differentiated low-immunogenic cardiomyocytes.
[0423] In one embodiment, the cardiomyocyte differentiation medium is a basal medium comprising a B27 additive that does not contain insulin. In one embodiment, the basal medium of the cardiomyocyte differentiation medium is selected from IMDM (Iscove's Modified Dulbecco's Medium) medium, Eagle's Basal Medium (BME) medium, MEM medium, DMEM medium, Ham's F-12 medium, RPMI1640 medium, Fischer's medium, E8 medium, mTESR medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF medium, StemMACS iPS Brew medium, Stem-Partner ACF medium, TeSR-AOF medium, TeSR2 medium, StemFit complete medium, PRMI1640 medium, mTESR1 medium. In a preferred embodiment, the cardiomyocyte differentiation medium is a PRMI1640 basal medium comprising a B27 additive that does not contain insulin.
[0424] In one embodiment, the GSK-3 inhibitor is selected from CHIR99021, GSK3β inhibitor IX, SB216763, GSK3β inhibitor VII, L803-mts, 6-bromo-indirubin-3'-oxime, TWS119, AZD2858, AR-A014418, TDZD-8, LY2090314, 2-D08, IM-12, 1-Azakenpaullone, and Indirubin.
[0425] In a preferred embodiment, the GSK-3 inhibitor comprises or is CHIR99021.
[0426] In one embodiment, the concentration of the GSK-3 inhibitor is 0.5 μM to 10 μM, preferably 6 μM.
[0427] In one embodiment, the concentration of the GSK-3 inhibitor CHIR99021 is 0.5 μM-10 μM, preferably 6 μM.
[0428] In one embodiment, the Wnt inhibitor comprises at least 1, 2, 3, or 4 selected from the group consisting of IWR-1, IWP-2, IWP-4, and C59.
[0429] In one embodiment, the Wnt inhibitor comprises at least one selected from IWR-1, IWP-2, IWP-4, and C59.
[0430] In a preferred embodiment, the Wnt inhibitor comprises or is IWR-1.
[0431] In one embodiment, the concentration of the Wnt inhibitor is 0.5 μM to 20 μM, preferably 2 μM.
[0432] In one embodiment, the concentration of the Wnt inhibitor IWR-1 is 0.5 μM to 20 μM, preferably 2 μM.
[0433] In one embodiment, the concentration of the insulin-free B27 supplement in the basal medium of the cardiomyocyte differentiation medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0434] In one embodiment, the method comprises:
[0435] adding CHIR99021 to a cardiomyocyte differentiation medium, and culturing low immunogenic pluripotent stem cells in the cardiomyocyte differentiation medium supplemented with CHIR99021;
[0436] The cardiomyocyte differentiation medium supplemented with CHIR99021 was replaced with cardiomyocyte differentiation medium and the cells were continued to be cultured;
[0437] IWR-1 was added to the cardiomyocyte differentiation medium, and the cells were continued to be cultured in the cardiomyocyte differentiation medium supplemented with IWR-1;
[0438] Replace the cardiomyocyte differentiation medium supplemented with IWR-1 with cardiomyocyte differentiation medium and continue culturing the cells; and
[0439] Obtain differentiated low-immunogenic cardiomyocytes;
[0440] The cardiomyocyte differentiation medium is a PRMI1640 basal medium containing a B27 supplement without insulin.
[0441] In one embodiment, the reduced immunogenicity pluripotent stem cells of the first aspect or the reduced immunogenicity pluripotent stem cells prepared by the method of the second aspect are cultured in a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor for 2 days. In one embodiment, the cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor is replaced with a cardiomyocyte differentiation medium, and the cells are cultured for another day. In one embodiment, a Wnt inhibitor is added to the cardiomyocyte differentiation medium, and the cells are cultured for another 2 days in the cardiomyocyte differentiation medium supplemented with the Wnt inhibitor. In one embodiment, the cardiomyocyte differentiation medium supplemented with a Wnt inhibitor is replaced with a cardiomyocyte differentiation medium, and the cells are cultured for another 10 days.
[0442] In one embodiment, the method comprises:
[0443] adding a GSK-3 inhibitor to a cardiomyocyte differentiation medium, and culturing the low immunogenicity pluripotent stem cells of the first aspect or the low immunogenicity pluripotent stem cells prepared by the method of the second aspect in the cardiomyocyte differentiation medium supplemented with the GSK-3 inhibitor for 2 days;
[0444] The cardiomyocyte differentiation medium supplemented with GSK-3 inhibitor was replaced with cardiomyocyte differentiation medium, and the cells were cultured for another day;
[0445] Wnt inhibitors were added to the cardiomyocyte differentiation medium, and the cells were cultured in the cardiomyocyte differentiation medium supplemented with Wnt inhibitors for another 2 days;
[0446] Replace the cardiomyocyte differentiation medium supplemented with Wnt inhibitors with cardiomyocyte differentiation medium and continue culturing the cells for 10 days; and
[0447] Obtain differentiated low-immunogenic cardiomyocytes.
[0448] In one embodiment, the method comprises:
[0449] CHIR99021 was added to the cardiomyocyte differentiation medium, and the low immunogenicity pluripotent stem cells were cultured in the cardiomyocyte differentiation medium supplemented with CHIR99021 for 2 days;
[0450] The cardiomyocyte differentiation medium supplemented with CHIR99021 was replaced with cardiomyocyte differentiation medium, and the cells were cultured for another day;
[0451] IWR-1 was added to the cardiomyocyte differentiation medium, and the cells were cultured in the cardiomyocyte differentiation medium supplemented with IWR-1 for another 2 days;
[0452] Replace the cardiomyocyte differentiation medium supplemented with IWR-1 with cardiomyocyte differentiation medium and continue culturing the cells for 10 days; and
[0453] Obtain differentiated low-immunogenic cardiomyocytes;
[0454] The cardiomyocyte differentiation medium is a PRMI1640 basal medium containing a B27 supplement without insulin.
[0455] The above method is a method for inducing low-immunogenicity pluripotent stem cells to differentiate into low-immunogenicity cardiomyocytes.
[0456] In one embodiment, the method further comprises culturing the reduced immunogenicity pluripotent stem cells in a basal medium comprising a ROCK inhibitor prior to culturing the reduced immunogenicity pluripotent stem cells in a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor.
[0457] In one embodiment, the method further comprises culturing the low immunogenicity pluripotent stem cells in a basal medium that does not comprise a ROCK inhibitor.
[0458] In one embodiment, the method further comprises culturing the low immunogenicity pluripotent stem cells in a basal medium comprising a ROCK inhibitor and culturing the low immunogenicity pluripotent stem cells in a basal medium not comprising a ROCK inhibitor before culturing the low immunogenicity pluripotent stem cells in a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor.
[0459] In one embodiment, the method further comprises culturing the low immunogenicity pluripotent stem cells in a basal medium comprising a ROCK inhibitor before culturing the low immunogenicity pluripotent stem cells in a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor, and then culturing the low immunogenicity pluripotent stem cells in a basal medium not comprising a ROCK inhibitor.
[0460] In one embodiment, the method further comprises culturing the low immunogenicity pluripotent stem cells in a basal medium containing a ROCK inhibitor for one day before culturing the low immunogenicity pluripotent stem cells in a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor, and then culturing the low immunogenicity pluripotent stem cells in a basal medium not containing a ROCK inhibitor for one day.
[0461] In one embodiment, the method comprises: when low immunogenic pluripotent stem cells cultured in a basal medium not containing a ROCK inhibitor grow to 85-98% confluence, replacing the basal medium not containing a ROCK inhibitor with a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor to induce differentiation.
[0462] Culturing low immunogenicity pluripotent stem cells in a basal medium comprising a ROCK inhibitor and / or culturing low immunogenicity pluripotent stem cells in a basal medium not comprising a ROCK inhibitor is a method for culturing low immunogenicity pluripotent stem cells to a cell confluence required for differentiation before induction of differentiation. In one embodiment, the cell confluence is 85-98%, including 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, preferably 95% confluence.
[0463] In one embodiment, the method further comprises culturing and maintaining the differentiated reduced immunogenic cardiomyocytes in a cardiomyocyte maintenance medium after obtaining the differentiated reduced immunogenic cardiomyocytes.
[0464] In one embodiment, the method comprises re-plating the differentiated reduced immunogenic cardiomyocytes after obtaining them, and then culturing and maintaining the differentiated reduced immunogenic cardiomyocytes in a cardiomyocyte maintenance medium.
[0465] Culturing and maintaining differentiated low immunogenic cardiomyocytes in a cardiomyocyte maintenance medium is a method for maintaining and culturing differentiated low immunogenic cardiomyocytes.
[0466] In a preferred embodiment, the ROCK inhibitor comprises or is Y-27632.
[0467] In one embodiment, the basal culture medium containing a ROCK inhibitor and / or the basal culture medium not containing a ROCK inhibitor is selected from IMDM (Iscove's Modified Dulbecco's Medium) medium, Eagle's Basal Medium (BME) medium, MEM medium, DMEM medium, Ham's F-12 medium, RPMI1640 medium, Fischer's medium, E8 medium, mTESR medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF medium, StemMACS iPS Brew medium, Stem-Partner ACF medium, TeSR-AOF medium, TeSR2 medium, StemFit complete medium, RPMI1640 medium, and mTESR1 medium.
[0468] In a preferred embodiment, the basal medium comprising a ROCK inhibitor and / or the basal medium not comprising a ROCK inhibitor comprises or is mTeSR1 basal medium.
[0469] In one embodiment, the cardiomyocyte maintenance medium is a basal medium comprising a B27 additive containing insulin. In one embodiment, the cardiomyocyte maintenance medium is selected from the group consisting of IMDM (Iscove's Modified Dulbecco's Medium) culture medium, Eagle's Basal Medium (BME) culture medium, MEM culture medium, DMEM culture medium, Ham's F-12 culture medium, RPMI1640 culture medium, Fischer's culture medium, E8 culture medium, mTESR culture medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF culture medium, StemMACS iPS Brew culture medium, Stem-Partner ACF culture medium, TeSR-AOF culture medium, TeSR2 culture medium, StemFit complete culture medium, PRMI1640 culture medium, and mTESR1 culture medium. In a preferred embodiment, the cardiomyocyte maintenance medium is a PRMI1640 basal medium comprising a B27 additive containing insulin.
[0470] In one embodiment, the concentration of the B27 supplement containing insulin in the basal medium of the cardiomyocyte maintenance medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0471] In one embodiment, the method comprises:
[0472] Culturing low-immunogenicity pluripotent stem cells in a basal medium containing a ROCK inhibitor;
[0473] The basal medium containing the ROCK inhibitor is replaced with a basal medium not containing the ROCK inhibitor, and the low immunogenicity pluripotent stem cells are continued to be cultured;
[0474] adding a GSK-3 inhibitor to a cardiomyocyte differentiation medium, replacing a basal medium not containing a ROCK inhibitor with a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor, and culturing low-immunogenicity pluripotent stem cells in the cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor;
[0475] The cardiomyocyte differentiation medium supplemented with GSK-3 inhibitor was replaced with cardiomyocyte differentiation medium and the cells were continued to be cultured;
[0476] adding a Wnt inhibitor to the cardiomyocyte differentiation medium and continuing to culture the cells in the cardiomyocyte differentiation medium supplemented with the Wnt inhibitor;
[0477] Replace the cardiomyocyte differentiation medium supplemented with Wnt inhibitors with cardiomyocyte differentiation medium and continue culturing the cells;
[0478] Obtaining differentiated low-immunogenic cardiomyocytes; and
[0479] Culture and maintain differentiated, low-immunogenic cardiomyocytes in Cardiomyocyte Maintenance Medium.
[0480] In one embodiment, the method comprises:
[0481] Culture low-immunogenicity pluripotent stem cells in mTeSR1 basal medium containing Y-27632;
[0482] Replace the mTeSR1 basal medium containing Y-27632 with mTeSR1 basal medium not containing Y-27632 and continue culturing the low-immunogenicity pluripotent stem cells;
[0483] CHIR99021 is added to the cardiomyocyte differentiation medium, mTeSR1 basal medium without Y-27632 is replaced with cardiomyocyte differentiation medium supplemented with CHIR99021, and low immunogenicity pluripotent stem cells are cultured in the cardiomyocyte differentiation medium supplemented with CHIR99021;
[0484] The cardiomyocyte differentiation medium supplemented with CHIR99021 was replaced with cardiomyocyte differentiation medium and the cells were continued to be cultured;
[0485] IWR-1 was added to the cardiomyocyte differentiation medium, and the cells were continued to be cultured in the cardiomyocyte differentiation medium supplemented with IWR-1;
[0486] Replace the cardiomyocyte differentiation medium supplemented with IWR-1 with cardiomyocyte differentiation medium and continue culturing the cells;
[0487] Obtaining differentiated low-immunogenic cardiomyocytes; and
[0488] Cultivate and maintain differentiated, low-immunogenic cardiomyocytes in cardiomyocyte maintenance medium;
[0489] The cardiomyocyte differentiation medium is a PRMI1640 basal medium containing a B27 additive without insulin, and the cardiomyocyte maintenance medium is a PRMI1640 basal medium containing a B27 additive with insulin.
[0490] In one embodiment, the hypoimmunogenic pluripotent stem cells are cultured in a basal medium containing a ROCK inhibitor for one day. In one embodiment, the basal medium containing a ROCK inhibitor is replaced with a basal medium not containing a ROCK inhibitor, and the hypoimmunogenic pluripotent stem cells are cultured for another day. In one embodiment, the differentiated hypoimmunogenic cardiomyocytes are cultured and maintained in a cardiomyocyte maintenance medium for 15 days.
[0491] In one embodiment, the method comprises:
[0492] Low immunogenicity pluripotent stem cells were cultured in basal medium containing ROCK inhibitor for 1 day;
[0493] The basal medium containing the ROCK inhibitor was replaced with a basal medium not containing the ROCK inhibitor, and the low immunogenicity pluripotent stem cells were cultured for another day.
[0494] Adding a GSK-3 inhibitor to cardiomyocyte differentiation medium, replacing the basal medium not containing a ROCK inhibitor with a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor, and culturing low-immunogenicity pluripotent stem cells in the cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor for 2 days;
[0495] The cardiomyocyte differentiation medium supplemented with GSK-3 inhibitor was replaced with cardiomyocyte differentiation medium, and the cells were cultured for another day;
[0496] Wnt inhibitors were added to the cardiomyocyte differentiation medium, and the cells were cultured in the cardiomyocyte differentiation medium supplemented with Wnt inhibitors for another 2 days;
[0497] The cardiomyocyte differentiation medium supplemented with Wnt inhibitors was replaced with cardiomyocyte differentiation medium, and the cells were cultured for another 10 days;
[0498] Obtaining differentiated low-immunogenic cardiomyocytes; and
[0499] Differentiated hypoimmunogenic cardiomyocytes were cultured and maintained in cardiomyocyte maintenance medium for 15 days.
[0500] In one embodiment, the method comprises:
[0501] Low immunogenicity pluripotent stem cells were cultured in mTeSR1 basal medium containing Y-27632 for 1 day;
[0502] The mTeSR1 basal medium containing Y-27632 was replaced with mTeSR1 basal medium not containing Y-27632, and the low immunogenicity pluripotent stem cells were cultured for another day.
[0503] CHIR99021 was added to the cardiomyocyte differentiation medium, and the mTeSR1 basal medium without Y-27632 was replaced with the cardiomyocyte differentiation medium supplemented with CHIR99021. The low immunogenicity pluripotent stem cells were cultured in the cardiomyocyte differentiation medium supplemented with CHIR99021 for 2 days.
[0504] The cardiomyocyte differentiation medium supplemented with CHIR99021 was replaced with cardiomyocyte differentiation medium, and the cells were cultured for another day;
[0505] IWR-1 was added to the cardiomyocyte differentiation medium, and the cells were cultured in the cardiomyocyte differentiation medium supplemented with IWR-1 for another 2 days;
[0506] The cardiomyocyte differentiation medium supplemented with IWR-1 was replaced with cardiomyocyte differentiation medium, and the cells were cultured for another 10 days;
[0507] Obtaining differentiated low-immunogenic cardiomyocytes; and
[0508] Differentiated low-immunogenic cardiomyocytes were cultured and maintained in cardiomyocyte maintenance medium for 15 days;
[0509] The cardiomyocyte differentiation medium is a PRMI1640 basal medium containing a B27 additive without insulin,
[0510] The cardiomyocyte maintenance medium is a PRMI1640 basal medium containing a B27 supplement containing insulin.
[0511] Prevention or treatment
[0512] In a third aspect, the present invention further provides use of the low immunogenicity pluripotent stem cells of the first aspect of the present invention or the low immunogenicity pluripotent stem cells prepared by the method of the second aspect of the present invention in preparing a medicament for preventing or treating a disease requiring cell transplantation.
[0513] The low immunogenicity pluripotent stem cells of the first aspect of the present invention or the low immunogenicity pluripotent stem cells prepared by the method of the second aspect of the present invention can be induced to differentiate into different cells, which can be used for different prevention or treatment purposes to prevent or treat different diseases. As will be understood by those skilled in the art, differentiation methods depend on the required cell types using known techniques. For example, cells can be suspended for differentiation and then made into a gel matrix form, such as matrigel, gelatin or fibrin / thrombin form, to promote cell survival. Usually differentiation can be determined as known in the art by assessing the presence of cell-specific markers. For example, cells can be differentiated into cardiomyocytes, neurons, glial cells, endothelial cells, T cells, NK cells, NKT cells, macrophages, hematopoietic progenitor cells, mesenchymal cells, islet cells, chondrocytes, retinal pigment epithelial cells, kidney cells, hepatocytes, thyroid cells, skin cells, blood cells or epithelial cells under certain differentiation conditions.
[0514] In some embodiments, the disease is cancer, and the cancer comprises solid tumors and hematological tumors. In some embodiments, the solid tumor comprises small cell lung cancer, breast cancer, testicular cancer, neuroblastoma, ovarian cancer, or melanoma. In some embodiments, the hematological tumor comprises acute leukemia, chronic leukemia, lymphoma, myelodysplastic syndrome, or multiple myeloma.
[0515] In one embodiment, the disease comprises aplastic anemia.
[0516] In one embodiment, the disease comprises an innate immune deficiency disease.
[0517] In some embodiments, the disease is an autoimmune disease comprising systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, or type I diabetes.
[0518] In some embodiments, the disease is a neurodegenerative disease comprising Parkinson's disease, Alzheimer's disease, spinal cord injury, retinal degeneration, stroke, Huntington's disease, or amyotrophic lateral sclerosis.
[0519] In some embodiments, the disease is a cardiovascular disease comprising atherosclerosis, hypertension, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, myocardial infarction, heart failure, aortic aneurysm, or peripheral arterial disease.
[0520] In some embodiments, the disease is a metabolic-related disease comprising type II diabetes, scurvy, hypoglycemia, hyperlipidemia, or osteoporosis.
[0521] In a seventh aspect, the present invention provides a low immunogenic cardiomyocyte, which is prepared by the kit of the fourth aspect or the method of the fifth aspect or the sixth aspect of the present invention.
[0522] In an eighth aspect, the present invention provides a cell therapeutic agent for preventing or treating heart disease, wherein the cell therapeutic agent comprises the low immunogenic cardiomyocytes according to the seventh aspect of the present invention.
[0523] In some embodiments, the heart disease includes, but is not limited to, myocardial infarction, angina pectoris, ischemic cardiomyopathy, primary cardiomyopathy, secondary cardiomyopathy, and heart failure. Beneficial effects
[0524] The pluripotent stem cells of the present invention and the low-immunogenic pluripotent stem cells prepared by the method of the present invention can exhibit excellent effects, such as but not limited to: (1) having good self-renewal and differentiation abilities; (2) being able to escape T cell killing; (3) being able to escape NK cell killing; (4) being able to escape macrophage killing and having excellent immune escape ability against macrophages; and / or (5) the differentiated cells can also escape T cell killing, NK cell killing and macrophage killing; thereby showing excellent application potential.
[0525] The pluripotent stem cells of the present invention and the cardiomyocytes derived from the low-immunogenicity pluripotent stem cells prepared by the method of the present invention can exhibit excellent effects, such as but not limited to: (1) having excellent expression of cardiomyocyte cell markers; (2) having the cell functions of cardiomyocytes, the presence of calcium ion oscillations in the cells, and excellent calcium transient frequency and amplitude; (3) being able to significantly restore the cardiac function of mice after transplantation into permanently ligated myocardial infarction mice; and / or (4) being able to escape T cell killing, NK cell killing and macrophage killing, and not activating the immune system in the body; thereby showing excellent application potential.
[0526] Example
[0527] The present invention is further described with reference to the following examples. It should be understood that these examples are intended to be illustrative only and are not intended to limit the present invention. Unless otherwise specified, the following materials and instruments are commercially available or prepared according to methods known in the art. Furthermore, unless otherwise specified, the following experiments were performed according to the manufacturer's instructions or according to methods and procedures known in the art.
[0528] Example 1. Construction of B2M and CIITA double knockout cell line (DKO)
[0529] 1.1 Construction of B2M and CIITA double knockout cell line (DKO)
[0530] In the following examples, human induced pluripotent stem cells (human iPS cells; in the following examples involving human induced pluripotent stem cells, they may also be referred to as hiPS cells or hiPSCs, or abbreviated as iPS cells or iPSCs), human pluripotent stem cell lines H1 (Wicell, WA01) or H9 (Wicell, WA09) were used to construct target cell lines. The cell culture and gene knockout reagents used are shown in Table 1.
[0531] Table 1. Cell culture and gene knockout reagents
[0532] CRISPR / CAS9 was used to knock out β-2-microglobulin (B2M) in the endoplasmic reticulum, preventing the formation of functional MHC-I molecules on the cell surface, thereby escaping allogeneic CD8 + Killing by T cells; killing by escaped CD4+ T cells is achieved by knocking out CIITA, a positive regulator of MHC-II gene transcription, thereby reducing the expression of MHC-II class molecules.
[0533] The CRISPR / CAS9 gene knockout strategy for B2M, as well as the gRNA sequences and identification primers used, are shown in Figure 1 and Table 2. B2M-gRNA1 and B2M-gRNA2 (EasyEdit sgRNA, GenScript) were used to directly knockout the B2M exon segment at both ends. The knockout was then verified against the genomic sequence using two pairs of PCR primers, B2M-F1 / R1 and B2M-F2 / R2. Figure 1(A) shows the knockout strategy for the B2M gene in the B2M and CIITA double knockout cell lines (DKO), Figure 1(B) shows the results of B2M gene knockout verification in the H1 cell line by PCR, and Figure 1(C) shows the results of B2M gene knockout verification in the iPS cell line by PCR.
[0534] In addition, the CRISPR / CAS9 gene knockout strategy for CIITA, as well as the gRNA sequences and identification primers used, are shown in Figure 2 and Table 2. CIITA-gRNA1 and CIITA-gRNA2 (EasyEdit sgRNA, GenScript) were used to directly knockout the CIITA exon segment at both ends. Then, two pairs of PCR primers, CIITA-F1 / R1 and CIITA-F2 / R2, were used to verify the genomic sequence knockout. Figure 2(A) shows the knockout strategy for the CIITA gene in B2M and CIITA double knockout cell lines (DKO), Figure 2(B) shows the results of CIITA gene knockout verification in the H1 cell line by PCR, and Figure 2(C) shows the results of CIITA gene knockout verification in the iPS cell line by PCR.
[0535] Table 2. gRNA sequences and identification primers
[0536] The specific operations are as follows:
[0537] 1) Culture human pluripotent stem cells H1 or human induced pluripotent stem cells iPSCs to 80% density in mTeSR1 medium supplemented with Y-27632 on a Matrigel-coated 6-well plate. Digest with TrypLE, neutralize with DMEM / F12, and count. Pipette 2×10 6 Place cells in EP tubes and discard the supernatant after centrifugation.
[0538] 2) According to the Neon transfection system (ThermoFisher), 100 μL electroporation system was added with 15 μg TrueCut TM Cas9 Protein + 3 μg gRNA (B2M-gRNA1 + B2M-gRNA2 + CIITA-gRNA1 + CIITA-gRNA2) constituted a ribonucleoprotein complex (RNP) system, which was mixed and placed at room temperature for 20 minutes.
[0539] 3) Resuspend the cells in 100 μL of RNP electroporation system and electroporate using the Neon transfection system at 1200 V, 30 ms, and 1 pause. Quickly add preheated culture medium to the electroporated cells and plate evenly in one well of a Matrigel-coated 6-well plate.
[0540] 4) Replace the culture medium with fresh mTeSR1 daily. Once single cells have grown, isolate individual clones in a 48-well plate. After clonal expansion, collect genomic samples for PCR analysis to verify gene editing. PCR results are shown in Figures 1 and 2. PCR-positive clones are sent to the company for further verification by Sanger sequencing.
[0541] 5) Expand, culture, and freeze the positive B2M / CIITA biallelic knockout (DKO) clones.
[0542] 1.2 Detection of RNA expression levels of B2M and CIITA in DKO
[0543] Total cellular RNA was extracted using the FastPure Cell / Tissue Total RNA Isolation Kit V2 (Novagen, RC112-01), and then converted to cDNA using HiScript III RT SuperMix for qPCR (Novagen, R323-01) according to the manufacturer's instructions.
[0544] qPCR was used to detect the expression of B2M and CIITA at the RNA level in the B2M / CIITA biallelic knockout H1 cell line clone DKO. The primers used are shown below.
[0545] B2M-F(SEQ ID NO:23):AAGATGAGTATGCCTGCCGT
[0546] B2M-R(SEQ ID NO:24):ATGCGGCATCTTCAAAACCTC
[0547] CIITA-F(SEQ ID NO:25):CCTGGAGCTTCTTAACAGCGA
[0548] CIITA-R(SEQ ID NO:26):TGTGTCGGGTTCTGAGTAGAG
[0549] Using the Roche 480II instrument, the reaction system is as follows:
[0550] Pre-incubation, 95℃, 30s.
[0551] Amplification, 95°C for 10 s, 60°C for 30 s, 40 cycles.
[0552] Melting curve and Cooling are the default programs.
[0553] The qPCR results are shown in Figure 3. Compared with untreated wild-type human pluripotent stem cells, the expression of B2M and CIITA at the RNA level in the H1 cell line clone DKO with B2M / CIITA biallelic knockout was almost absent, confirming the successful knockout of B2M and CIITA.
[0554] 1.3 Detection of B2M protein expression in DKO
[0555] Western blotting was used to detect the expression of B2M protein levels in the B2M / CIITA biallelic knockout H1 cell line clone DKO (the B2M antibody is ab75853; the internal control antibody GAPDH is ab181602, both purchased from Abcam).
[0556] The Western blot results are shown in Figure 4. Compared with wild-type human pluripotent stem cells, the B2M protein in the H1 cell line DKO was significantly decreased, confirming that the B2M protein was successfully knocked out.
[0557] 1.4 Detection of HLA-I / II molecules in DKO
[0558] IFN-γ (PeproTech, Cat#300-02) was used to stimulate H1 cell line WT, iPS cell line WT, H1 cell line DKO, and iPS cell line DKO to detect HLA class I / II molecules on the cell surface. The specific detection method is as follows:
[0559] The cells were plated and cultured the next day with IFN-γ-containing medium added to the cells. After 48 hours, the cells were digested and HLA-I / II expression was assessed using a flow cytometer (Agilent Technologies, NovoCyte). The flow cytometric results are shown in Figures 5A-D, which show that stem cell-positive clones of the B2M / CIITA biallelic knockout H1 and iPS cell lines (DKO) failed to express HLA-I / II molecules in response to IFN-γ stimulation. Figures 5A and 5B show the results for the H1 cell line, while Figures 5C and 5D show the results for the iPS cell line. Figures 5A and 5C measure HLA-I molecule levels (i.e., HLA-ABC), while Figures 5B and 5D measure HLA-II molecule levels (i.e., HLA-DR, DQ, DP). T cells served as a positive control for HLA-I / II molecule detection. Flow cytometry results demonstrated that the functions of HLA-I and HLA-II in the two DKO cell lines were reduced.
[0560] 1.5 Karyotyping of DKO
[0561] Karyotype detection was performed on the obtained B2M / CIITA biallelic knockout (DKO) H1 cell line positive clones. The specific detection method is as follows:
[0562] Chromosome specimens fixed on glass slides are treated with trypsin and then stained with Giemsa stain. Metaphase chromosomes are analyzed for number and morphology based on characteristics such as chromosome length, centromere position, ratio of long and short arms, and the presence of satellites to determine whether their karyotype is consistent with a normal karyotype.
[0563] The results of karyotype detection are shown in Figure 6 . The karyotype of the H1 cell line DKO is normal, with no significant changes compared with the normal karyotype.
[0564] Example 2. Stemness and immune function of DKO cell lines
[0565] This example further examines whether the stemness and immune function of pluripotent stem cells change after knocking out both B2M / CIITA alleles.
[0566] 2.1 Expression of stemness genes in DKO cells
[0567] Immunofluorescence was used to detect the protein levels of the stemness genes POU5F1 and NANOG in WT and DKO cells of the H1 cell line, and the protein levels of the stemness genes TRA-1-60, TRA-1-81, OCT-4, SOX2, and NANOG were detected in WT and DKO cells of the iPS cell line. RT-qPCR was used to detect the RNA expression of the stemness genes POU5F1, NANOG, and SOX2 in WT and DKO cells of the H1 cell line. Flow cytometry was used to detect the cell surface expression of the stemness genes SSEA-4 and TRA-1-81 in WT and DKO cells of the H1 cell line, and the cell surface expression of the stemness genes SSEA-4, TRA-1-60, TRA-1-81, OCT-4, and SOX2 in WT and DKO cells of the iPS cell line. The specific detection methods are as follows:
[0568] Immunofluorescence assay: WT or DKO cells were plated in 12-well plates. After cells reached 60-80% confluence, the medium was aspirated and fixed with 4% paraformaldehyde. After permeabilization, cells were incubated with primary antibodies against POU5F1, NANOG, TRA-1-60, TRA-1-81, OCT-4, or SOX2 at 4°C overnight. After washing away the primary antibodies, fluorescently labeled secondary antibodies were incubated at room temperature. Images were then taken using a fluorescence microscope (Nikon Ts2R-FL).
[0569] RT-qPCR detection:
[0570] Using the Roche 480II instrument, the reaction system is as follows:
[0571] Pre-incubation, 95℃, 30s.
[0572] Amplification, 95°C for 10 s, 60°C for 30 s, 40 cycles.
[0573] Melting curve and Cooling are the default programs.
[0574] Mesenchymal stem cells (MSCs) served as a negative control for stemness gene expression.
[0575] Flow cytometry:
[0576] After harvesting the cells, incubate the antibodies in an EP tube at 4°C in the dark for 30 minutes. Then, select the appropriate fluorescence acquisition channel based on the antibody information and monitor the fluorescence on a fluorescence microscope. All antibodies were from BD Biosciences.
[0577] The results of immunofluorescence analysis of the H1 cell line are shown in Figure 7A. Both WT and DKO cells of the H1 cell line express the stemness genes POU5F1 and NANOG at the protein level, and the expression of these genes in DKO cells is not significantly different from that in WT cells. The results of RT-qPCR analysis of the H1 cell line are shown in Figure 7B. Both WT and DKO cells of the H1 cell line express the stemness genes POU5F1, NANOG, and SOX2 at the RNA level, and the expression of these genes in DKO cells is not significantly different from that in WT cells.
[0578] The flow cytometry results of the H1 cell line and iPS cell line are shown in Figures 8A-B. Figure 8A shows that both the H1 cell line WT and the H1 cell line DKO highly express the stemness genes SSEA-4 and TRA-1-81 on their cell surfaces, accounting for 100% and 99.98% (SSEA-4) and 96.75% and 99.13% (TRA-1-81), respectively. Figure 8B shows the results of flow cytometry detection of the expression of stemness genes SSEA-4, TRA-1-60, TRA-1-81, OCT-4, and SOX2 on the cell surfaces of iPSC-WT and iPSC-DKO cells. The results of immunofluorescence detection of iPS cell lines are shown in Figures 8C-D. Figure 8C shows the results of immunofluorescence detection of the protein levels of stemness genes TRA-1-60, TRA-1-81, OCT-4, SOX2, and NANOG in iPSC-WT cells; Figure 8D shows the results of immunofluorescence detection of the protein levels of stemness genes TRA-1-60, TRA-1-81, OCT-4, SOX2, and NANOG in iPSC-DKO cells.
[0579] Differentiation capacity of 2.2DKO cells
[0580] In this example, the differentiation ability of H1 cell line DKO cells was detected. The specific detection method was as follows: 100 μL containing 5×10 5 DKO cell suspension was prepared and the teratoma volume was larger than 1.5 cm 3 The tissues were then removed, sectioned into paraffin and stained with hematoxylin and eosin.
[0581] The staining results are shown in Figure 9 . The B2M / CIITA biallelic knockout H1 cell line DKO cells can form teratomas in vivo and differentiate into cells of the inner, middle and outer germ layers. The DKO cells have normal differentiation ability of the three germ layers.
[0582] 2.3 Immune function of DKO cells
[0583] T cell and NK cell cytotoxicity assays were performed using the xCELLigence RTCA Instrument to examine changes in immune function in H1 and iPS cell lines. Reagents used in these cytotoxicity assays are listed in Table 3.
[0584] The specific detection method is as follows: Equal amounts of WT and DKO H1 and iPS cell lines were resuspended in Essential 8 medium containing human IL-2 and seeded onto 96-well E-plates coated with Matrigel. Activated T cells (XC11228, purchased from SAILYBIO) or NK cells (XC11013, purchased from SAILYBIO) were added for killing assays. T cells were assayed for CD3, CD4, and CD8 by flow cytometry before use, and NK cells were assayed for CD16 and CD56 by flow cytometry before use to ensure the functionality of the T and NK cells used. RTCA assay data were analyzed using xCELLigence software to calculate killing rate and escape function.
[0585] Table 3. Reagents used in the killing experiment
[0586] The RTCA results are shown in Figures 10A (H1 cell line) and 10B (iPS cell line). WT cells of the H1 and iPS cell lines escape NK cell killing due to the expression of HLA-I, but are killed by T cells; DKO cells can escape T cell killing and are more sensitive to NK cell killing.
[0587] Example 3. Construction of DKO+CD47 cell line and verification of immune function
[0588] 3.1 Construction of DKO+CD47 cell line
[0589] In this example, a lentiviral vector was used to overexpress CD47 (NM_198793) in the H1 cell line DKO cells obtained in Example 1. The amino acid sequence of CD47 is shown in SEQ ID NO: 5.
[0590] The nucleic acid sequence encoding the CD47 protein (SEQ ID NO: 6) was constructed into a lentiviral vector (pGC-EF1a) driven by EF1a and carrying a puromycin selection marker. The structure of the pGC-EF1a vector is shown in Figure 11. The specific operation method is as follows:
[0591] The lentiviral vector was digested with BamHI / NheI, and the nucleic acid sequence encoding the CD47 protein (SEQ ID NO: 6) was ligated into the lentiviral vector. Sanger sequencing was used to verify the correctness of the inserted sequence, and viral packaging was performed. The lentiviral vector was transfected into the H1 cell line DKO cells constructed in Example 1. After 24 hours, the medium was replaced with puromycin-containing medium for selection after 48 hours.
[0592] The constructed stably transfected H1 cell line DKO+CD47 was analyzed by flow cytometry (CD47 antibody purchased from Biolegend, FACS, Cat. No. 323108) and qPCR. The qPCR primers were CD47-F (SEQ ID NO: 29): AGAAGGTGAAACGATCATCGAGC; CD47-R (SEQ ID NO: 30): CTCATCCATACCACCGGATCT.
[0593] The test results are shown in Figures 12A and 12B. The expression level of CD47 in the constructed H1 cell line DKO+CD47 cells was significantly higher than that in WT cells. The validated H1 cell line DKO+CD47 cells were then expanded and subsequently functionally tested.
[0594] 3.2 Verification of the immune function of DKO+CD47
[0595] RTCA was used to detect whether the overexpressed H1 cell line DKO+CD47 cell line could successfully escape the killing of NK cells while escaping T cell killing. For the specific detection method, see Example 2.3.
[0596] As shown in Figure 13 , RTCA assay showed that NK cells could effectively kill H1 cell line DKO cells, while H1 cell line WT and H1 cell line DKO+CD47 overexpressing cells could escape NK killing.
[0597] Example 4. Construction of DKO+CD68 cell line and detection of stemness and differentiation ability
[0598] 4.1 Construction of DKO+CD68 cell line and overexpression detection
[0599] The nucleic acid sequence encoding the CD68 protein (the amino acid sequence of the CD68 protein is shown in SEQ ID NO: 3) was directly synthesized. The nucleic acid sequence is shown in SEQ ID NO: 4.
[0600] As described in Example 3.1, the nucleic acid sequence encoding the CD68 protein was constructed in a lentiviral vector (pGC-EF1a) driven by EF1a and carrying a puromycin selection marker. The structure of the pGC-EF1a vector is shown in Figure 11. The specific operation is as follows: the vector is digested with BamHI / NheI, and the above-synthesized CD68 nucleic acid sequence is connected to the lentiviral vector. After successful connection, Sanger sequencing is used to verify the correctness of the inserted sequence and viral packaging is performed. The lentiviral vector is transfected into the H1 cell line or iPS cell line DKO cells constructed in Example 1. The medium is changed after 24 hours, and after 48 hours, the medium is changed to a medium with puromycin for selection.
[0601] The constructed H1 cell line DKO+CD68 cells were used to detect the overexpression level of mRNA using qPCR and RT-PCR, and WT cells were used as negative controls. The primers used are shown in Table 4.
[0602] Table 4. qPCR detection primers for CD68
[0603] The detection results are shown in FIG14 , which show that CD68 is highly expressed in the constructed H1 cell line DKO+CD68 cells.
[0604] 4.2 Expression of stemness genes in the DKO+CD68 cell line
[0605] The expression of stemness genes in H1 cell line DKO+CD68 cells was detected by immunofluorescence and flow cytometry. For specific detection methods, see Example 2.1.
[0606] The results of immunofluorescence detection are shown in Figure 15A , and the constructed H1 cell line DKO+CD68 cells expressed stemness genes OCT4, NANOG, SOX2, TRA-1-60, and TRA-1-81 at the protein level.
[0607] The flow cytometry results are shown in Figure 15B . The stemness genes SSEA-4, TRA-1-60, TRA-1-81, and OCT4 were highly expressed on the cell surface of the H1 cell line DKO+CD68 cells, with the proportions of each stemness gene being 98.09%, 99.83%, 99.11%, and 96.97%, respectively.
[0608] 4.3 Differentiation capacity of the three germ layers of the DKO+CD68 cell line
[0609] H1 cell line DKO+CD68 cells were used to test the ability of three germ layers to differentiate. In order to generate mesoderm, endoderm, and ectoderm cells, the dissociated H1 cell line DKO+CD68 single cells were resuspended in three germ layer culture media supplemented with Y27632, and an appropriate amount of cells were attached to a well plate coated with a matrix gel with a cell crawler. After 24 hours, the culture medium was replaced with preheated differentiation medium, and the medium was changed every day until the seventh day to obtain mesoderm, endoderm, and ectoderm cells. The expression of three germ layer marker proteins was detected by immunofluorescence to detect the three germ layer differentiation ability of H1 cell line DKO+CD68 cells.
[0610] The results of immunofluorescence detection are shown in FIG16 . H1 cell line DKO+CD68 cells express ectoderm marker proteins: PAX6 and GAD1; mesoderm marker proteins: Brachyury and NCAM; and endoderm marker proteins: SOX17 and FOXA2 at the protein level.
[0611] 4.4 Teratoma-forming ability of the DKO+CD68 cell line
[0612] This example tests the differentiation ability of H1 cell line DKO+CD68 cells. The specific test method is as follows: 100 μL containing 5×10 5 H1 cell line DKO+CD68 cell suspension, wait until the teratoma volume is larger than 1.5cm 3 The tissues were then removed, sectioned into paraffin and stained with hematoxylin and eosin.
[0613] FIG17 shows the results of the teratoma formation ability test, where it can be seen that the H1 cell line DKO+CD68 cells formed teratomas in vivo and differentiated into cells of the endoderm, mesodermal and ectoderm.
[0614] Example 5 Immune escape function of DKO+CD68 cell line
[0615] To verify the escape function of H1 and iPS cell lines DKO+CD68 cells against different immune cells, experiments were performed using NK cells, a mixture of T cells + NK cells, and macrophages.
[0616] 5.1 Detection of immune escape function of DKO+CD68 cells using RTCA
[0617] RTCA was used to assess the ability of H1 and iPS cell lines (DKO+CD68) to escape various immune cells. For detailed assay methods, see Example 2.3. The PBNK cells used were obtained by supplementing PBMC (peripheral blood mononuclear cells, sourced from SAILYBIO) with IL-2 during in vitro culture to increase the NK cell population to 20%-30%.
[0618] DKO+CD68 cells from H1 and iPS cell lines resist NK cell cytotoxicity: NK cell cytotoxicity assays were performed on the XCelligence platform (ACEA BioSciences). Each type of iPSC and ESC was resuspended in 100 μL of cell culture medium and plated onto 96-well E-plates (ACEA BioSciences) coated with Matrigel (Sigma-Aldrich). After the cell index (reflecting cell number) reached 1, NK cells were added at an E:T ratio (effector:target ratio) of 2:1 (H1 cell line) and 1:1 (iPS cell line), respectively. Data were normalized and analyzed using RTCA software (ACEA). The results showed that DKO+CD68 cells from H1 and iPS cell lines significantly evaded NK cell cytotoxicity.
[0619] H1 and iPS cell line DKO+CD68 cells resist PBMC cytotoxicity: NK activator (IL-2) was added to PBMCs in advance to increase the proportion of NK cells in PBMCs and the cytotoxicity of T cells. Activated mixed lymphocytes (PBNKs) were used as effector cells in RTCA experiments to comprehensively evaluate the immune escape ability of H1 and iPS cell line DKO+CD68 cells (refer to Liu M, et al. High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18. Biochem Biophys Res Commun. 2021 Jan 1; 534:149-156.). PBNK cell cytotoxicity was determined on the XCelligence platform (ACEA BioSciences). Each type of iPSC and ESC was resuspended in 100 μL of cell culture medium and plated onto 96-well E-plates coated with Matrigel (ACEA BioSciences). After the cell index reached 1, PBNK was added at an E:T ratio of 2:1. Data were normalized and analyzed using RTCA software (ACEA). The results showed that H1 and iPS cell lines (DKO+CD68 cells) significantly evaded PBNK cytotoxicity, with greater evasion than WT cells.
[0620] H1 cell line DKO+CD68 cells resist macrophage killing: MAC cell (macrophage) killing assays were performed on the XCelligence platform (ACEA BioSciences). H1 cells were resuspended in 100 μL of cell culture medium and plated in 96-well E-plates coated with Matrigel (ACEA BioSciences). After the cell index reached 1, MAC cells were added at a 1:1 E:T ratio. Data were normalized and analyzed using RTCA software (ACEA). The results showed that H1 cell line DKO+CD68 cells significantly evaded MAC killing.
[0621] The test results are shown in Figures 18A-D, 19A-D, and 20A-B. In the NK cell killing experiment detected by RTCA, the H1 and iPS cell line DKO cells constructed in Example 1 were completely killed by NK cells, while the H1 and iPS cell line WT cells and the H1 and iPS cell line DKO+CD68 cells successfully escaped (Figures 18A, 18B, 18C, and 18D). In the mixed cell killing experiment of T cells and NK cells (PBNK) detected by RTCA, only the H1 and iPS cell line DKO+CD68 cells successfully escaped, and the H1 and iPS cell line WT cells and the H1 and iPS cell line DKO cells were killed to varying degrees, among which the H1 and iPS cell line DKO cells were completely killed (Figures 19A, 19B, 19C, and 19D). In the macrophage cytotoxicity assay using RTCA, DKO+CD68 cells from the H1 cell line successfully escaped, significantly outperforming the existing DKO+CD47 cells. Both WT and DKO cells from the H1 cell line were killed (Figures 20A and 20B). Figures 18B, 18D, 19B, 19D, and 20B show statistical plots of multiple kills.
[0622] 5.2 Detection of NK cell IFN-γ spot secretion using ELISpot
[0623] Referring to the method described in "Maggioli MF, et al. Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle. J Vis Exp. 2015 Jul 11; (101): e52833," NK cell IFN-γ spot secretion was detected by ELISpot to determine the immune escape function of DKO+CD68 cells. The specific operation method is as follows:
[0624] Appropriate amounts of H1 cell line WT cells, H1 cell line DKO cells, and H1 cell line DKO+CD68 cells were plated in 96-well plates. After 24 hours, the culture medium was discarded and an appropriate amount of NK cells were added for culture. After 24 hours, NK cells were collected for subsequent IFN-γ secretion detection. At the same time, the remaining H1 cell line WT cells, H1 cell line DKO cells, and H1 cell line DKO+CD68 cells after the NK cells were removed were observed. The results are shown in Figure 21. Compared with H1 cell line DKO cells, H1 cell line WT cells and H1 cell line DKO+CD68 cells were killed by NK cells less, indicating that the ability of H1 cell line DKO+CD68 cells to escape NK cell killing is significantly higher than that of DKO cells.
[0625] The NK cells collected after 24 hours were plated in a 96-well plate coated with IFN-γ antibody and incubated in a 37°C incubator for 24 hours; affinity antibody and streptavidin were added for incubation and IFN-γ secretion spots were detected by color development.
[0626] The ELISpot test results are shown in Figures 22A and 22B. The number of spots formed by IFN-γ secreted by NK cells stimulated by H1 cell line WT cells and H1 cell line DKO+CD68 cells after co-culture with NK cells was similar, and both were significantly lower than that of DKO cells, indicating that overexpression of CD68 can offset the NK cell activation caused by B2M / CIITA knockout.
[0627] Example 6. Verification of Immune Escape of Differentiated Cells of DKO+CD68 Cells
[0628] Plate cells onto Matrigel and, when confluence reaches 40%, switch to differentiation medium daily. Once confluent, subculture onto 0.1% gelatin-coated dishes and perform subculture every 3 days, continuing with daily medium changes. The differentiation cycle is 10 days.
[0629] The escape ability of differentiated cells of the H1 cell line DKO+CD68 cells to NK cells, mixed T cells+NK cells, and macrophages was detected by RTCA. Specific detection methods are shown in Example 2.3.
[0630] The test results are shown in Figures 23A and 23B, Figures 24A and 24B, and Figures 25A and 25B. In the NK cell killing experiment detected by RTCA, the H1 cell line DKO cells were still completely killed by NK cells after differentiation, while the differentiated cells of the H1 cell line WT cells and the differentiated cells of the H1 cell line DKO+CD68 cells successfully escaped the killing of NK cells (Figures 23A and 23B). In the mixed cell (PBNK) killing experiment of T cells+NK cells detected by RTCA, only the differentiated cells of the H1 cell line DKO+CD68 cells successfully escaped (Figures 24A and 24B). In the macrophage killing experiment detected by RTCA, the differentiated cells of the H1 cell line DKO+CD68 cells still showed the escape ability of the differentiated cells that were significantly better than the prior art DKO+CD47 cells, while the differentiated cells of the H1 cell line WT and H1 cell line DKO cells were killed (Figures 25A and 25B). Figures 23B, 24B, and 25B are multiple kill statistics.
[0631] Example 7. Construction and verification of NHP iPSC-DKO cells
[0632] 7.1 Construction of NHP iPSC-DKO cells
[0633] Cynomolgus monkey iPSC-DKO (i.e., non-human primate (NHP) iPSC-DKO cells, also referred to herein as NHP DKO) was generated according to the method described in Example 1. Specifically, cynomolgus monkey adult cells (collected from 5-10 year old male cynomolgus monkeys) were collected and cultured by CTS. TM CytoTune TM Cynomolgus macaque iPS cells were prepared using the iPS 2.1 Sendai virus reprogramming kit (Cat. No. A34546). The expression of stemness genes and teratoma formation in cynomolgus macaque iPSC-DKO cells were assayed according to the method described in Example 2. As shown in Figures 26A and 26B, NHP iPSC-DKO cells expressed the stemness genes TRA-1-60, TRA-1-81, SOX2, NANOG, and OCT4 at the protein level, and they could form teratomas in vivo and differentiate into cells of the inner, middle, and outer germ layers. NHP iPSC-DKO cells have normal three-germ layer differentiation capacity.
[0634] NHP-B2M-gRNA1 and NHP-B2M-gRNA2 were used to directly knock out the B2M exon segment at both ends, and then a pair of PCR primers NHP-B2M-F / R was used to perform genome sequence knockout verification. In addition, NHP-CIITA-gRNA1 and NHP-CIITA-gRNA2 were used to directly knock out the CIITA exon segment at both ends, and genome PCR was performed to verify genome knockout by a pair of PCR primers NHP-CIITA-F / R (gRNA sequence and identification primer sequence are shown in Table 5). Two monoclonal NHP iPSC-DKO (ie, NHP iPSC-DKO1 and NHP iPSC-DKO2 cells below) were selected for subsequent experiments.
[0635] Table 5. gRNA sequences and identification primer sequences
[0636] 7.2 Detection of HLA-I / II Molecular Expression in NHP iPSC-DKO
[0637] IFN-γ (PeproTech, Cat#300-02) was used to stimulate NHP iPSC-WT, NHP iPSC-DKO1, and NHP iPSC-DKO2 cells to detect HLA class I / II molecules on the cell surface. The specific detection method is as follows:
[0638] Cells were plated in well plates and cultured with IFN-γ-containing medium during the next day's culture. After 48 hours, the cells were digested and HLA-I / II expression was measured using a flow cytometer (Agilent Technologies, NovoCyte).
[0639] The flow cytometry results are shown in Figure 27 . B2M / CIITA biallelic knockout NHP iPSC-DKO1 and NHP iPSC-DKO2 cells do not express HLA-I / II and cannot upregulate HLA-I / II in response to IFN-γ stimulation.
[0640] 7.3 Detection of immune escape function of NHP iPSC-DKO
[0641] T cell killing assays were performed on the XCelligence platform (ACEA BioSciences) to detect changes in the immune function of NHP iPSC-DKO cells. The specific detection methods and results are described below.
[0642] NHP iPSC-WT (also referred to herein as NHP WT cells) and iPSC-DKO cells were resuspended in 100 μL of cell culture medium and plated on 96-well E-plates coated with Matrigel (ACEA BioSciences). After the cell index reached 1, T cells (isolated from blood collected from cynomolgus macaques) were added at an E:T ratio of 2:1. Data were normalized and analyzed using RTCA software (ACEA). As shown in Figure 28, NHP iPSC-DKO cells significantly evaded T cell cynomolgus ...
[0643] Example 8. Construction and verification of NHP iPSC-DKO+CD68 cells
[0644] 8.1 Construction and Overexpression Detection of NHP iPSC-DKO+CD68 Cells
[0645] NHP iPSC-DKO+CD68 cells (also referred to herein as NHP DKO+CD68) were prepared referring to the method in Example 4.1. Specifically, a nucleic acid sequence encoding CD68 protein (the amino acid sequence of CD68 protein is shown in SEQ ID NO: 7) was directly synthesized (as shown in SEQ ID NO: 8). The synthesized nucleic acid sequence of CD68 was connected to a lentiviral vector. After successful connection, the correctness of the inserted sequence was verified and viral packaging was performed. The lentiviral vector was transfected into the NHP iPSC-DKO cells constructed in Example 7. RT-qPCR was used to detect the overexpression level of cynomolgus monkey CD68 mRNA, WT cells were used as a negative control, and the primers used were shown in Table 6.
[0646] Table 6. qPCR primers for cynomolgus monkey STC1
[0647] The detection results are shown in FIG29 , which show that CD68 is highly expressed in the constructed NHP iPSC-DKO+CD68 cells.
[0648] 8.2 Detection of immune escape function of NHP iPSC-DKO+CD68 cells
[0649] 8.2.1 NHP iPSC-DKO+CD68 cells resist cynomolgus monkey NK cell killing in vitro
[0650] An NK cell killing assay was performed on the XCelligence platform (ACEA BioSciences) to examine the immune evasion capabilities of the universal NHP iPSC-DKO+CD68 cells. Specifically, NHP iPSC-WT, NHP iPSC-DKO, and NHP iPSC-DKO+CD68 cells were resuspended in 100 μL of cell culture medium and plated onto 96-well E-plates coated with Matrigel (ACEA BioSciences). After the cell index reached 1, NK cells (isolated from blood collected from cynomolgus macaques) were added at a 1:1 E:T ratio. Data were normalized and analyzed using RTCA software (ACEA). As shown in Figure 30, NHP-WT and NHP iPSC-DKO+CD68 cells significantly evaded cynomolgus macaque NK cell killing.
[0651] 8.2.2 NHP iPSC-DKO+CD68 cells resist cynomolgus monkey PBMC killing in vitro
[0652] A PBMC killing assay was performed on the XCelligence platform (ACEA BioSciences) to examine the immune evasion ability of the universal NHP iPSC-DKO+CD68 cell line. Specifically, NHP iPSC-WT, NHP iPSC-DKO, and NHP iPSC-DKO+CD68 cells were resuspended in 100 μL of cell culture medium and plated onto 96-well E-plates coated with Matrigel (ACEA BioSciences). After the cell index reached 1, IL-2-activated PBMCs (isolated from blood collected from cynomolgus macaques), also known as PBNK cells, were added at a 1:1 E:T ratio. Data were normalized and analyzed using RTCA software (ACEA). As shown in Figure 31, NHP iPSC-DKO+CD68 cells significantly evaded cynomolgus macaque PBNK cell killing, while NHP-WT and NHP-DKO cells were killed to varying degrees by cynomolgus macaque PBNK cells.
[0653] 8.2.3 Immune Escape Function of NHP iPSC-DKO+CD68 Cells in Vivo
[0654] a) Survival rate of transplanted cells
[0655] In this example, bioluminescence imaging (BLi) was performed to monitor the viability of universal NHP iPSC-DKO+CD68 cells after injection of cells into NHPs or into immunodeficient NOG mice. For BLi, D-luciferin firefly potassium salt (375 mg / kg) (Biosynth AG) was dissolved in sterile PBS (pH 7.4) (Gibco, Invitrogen) and injected intravenously into anesthetized cynomolgus monkeys or intraperitoneally into anesthetized mice. Animals were imaged using Largo (Spectral Instruments Imaging, Tucson, AZ). The region of interest (ROI) bioluminescence was expressed as the maximum number of photons / second / square centimeter / steradian (p / s / cm 2 The units of / sr) are used for quantification.
[0656] The specific experimental operation was as follows: NHP iPSC-WT and NHP iPSC-DKO+CD68 cells were infected with lentivirus carrying luciferase (luc) (Gene Gene), and the infected NHP iPSC-WT and NHP iPSC-DKO+CD68 cells were subcutaneously injected into cynomolgus monkeys or NOG mice (Vitamin B, female) (the mouse cell injection dose was 1E+6, and the cynomolgus monkey cell injection dose was 1E+7). The bioluminescence in cynomolgus monkeys was observed on days 0, 1, 4, and 7 after cell injection, and the bioluminescence in NOG mice was observed on days 0, 3, 7, 11, 14, 21, and 35 after cell injection. The specific bioluminescence detection method involves intravenous injection (cynomolgus monkeys) or intraperitoneal injection (NOG mice) of the luc substrate, D-luciferin firefly potassium salt. Fifteen minutes after substrate injection, the fluorescence intensity of the cells is measured using an in vivo imaging system (iVIS spectrum, PerkinElmer). The fluorescence intensity of the cells indicates cell survival in NHP or NOG mice. The bioluminescence imaging results for NHPs are shown in Figure 32(A). The in vivo fluorescence signal of NHPs in the NHP iPSC-DKO+CD68 cell-injected group is significantly higher than that in the NHP iPSC-WT cell-injected group. The bioluminescence imaging results for NOG mice are shown in Figure 32(B). Both NHP iPSC-WT and NHP iPSC-DKO+CD68 cells can sustain growth in NOG mice. The observed difference in survival time between NHP iPSC-DKO+CD68 and NHP iPSC-WT cells in NHPs is due to the speed of rejection by the immune system, indicating that NHP iPSC-DKO+CD68 cells are resistant to immune rejection and have low immunogenicity.
[0657] b) The degree of activation of the immune system by transplanted cells
[0658] Referring to the method in Example 5.2, the degree of immune activation of immune cells in cynomolgus monkeys was assessed by ELISpot assay on day 0 and day 7 after cell transplantation. The ELISpot assay results are shown in Figure 33. The number of spots formed by IFN-γ secretion stimulated by NHP iPSC-DKO+CD68 cells transplanted into cynomolgus monkeys was significantly lower than that of NHP iPSC-WT cells, indicating that transplantation of NHP universal cells overexpressing CD68 hardly activates the immune system in vivo.
[0659] Example 9. Inducing DKO+CD68 cells of iPS cell line to differentiate into iCMs
[0660] 9.1 Inducing the differentiation of universal stem cells into iCMs in vitro
[0661] The process of differentiating WT cells and DKO+CD68 cells of the iPS cell line into iCM (i.e., iPSC-derived cardiomyocytes (CM)) in vitro is shown in Figure 34. The specific operation is as follows: when the hiPS cells grow to about 95% confluence, the cells are first washed with DPBS, and then 1 mL of ethylenediaminetetraacetic acid (versene) is added and digested at 37°C for 5 minutes. The versene is aspirated, and the cells are pipetted into single cells with 1 mL of mTeSR1 containing 10 mL of Y-27632, and then counted and counted according to 2×10 5Cells were seeded at a density of 10 cells / well in Matrigel-coated 12-well plates, marking day -2 of differentiation induction. On day -1 of differentiation induction, cells were cultured for another day in fresh mTeSR1 medium without Y-27632. On day 0 of differentiation induction, when cells reached approximately 95% confluence, the medium was changed to cardiomyocyte differentiation medium, consisting of PRMI1640 basal medium and insulin-free B27 supplement. On days 0-2 of differentiation induction, cells were cultured for two days in cardiomyocyte differentiation medium supplemented with 6 mM CHIR99021. On day 2 of differentiation induction, the medium was changed to fresh cardiomyocyte differentiation medium and the cells were cultured for another day. On days 3-5 of differentiation induction, cells were cultured for two days in cardiomyocyte differentiation medium supplemented with 2 mM IWR-1. On day 5 of differentiation induction, the medium was changed to fresh cardiomyocyte differentiation medium and the medium was changed every two days for continued culture. Spontaneous beating cells were observed on day 7 of differentiation induction. On the 15th day of differentiation induction, the culture medium was discarded and 500 mL of trypleExpress was added to each well and digested at 37°C for 15 minutes. The cells were pipetted and the cell suspension was collected. The wells were rinsed with cardiomyocyte differentiation medium to collect the remaining cells. The cell suspension was then filtered through a nylon filter with a 70 mm pore size and centrifuged at 200 g for 5 minutes. The cell pellet was resuspended in cardiomyocyte maintenance medium (cardiomyocyte maintenance medium includes PRMI1640 basal medium and B27 supplement containing insulin) and the cell pellet was diluted to 4 × 10 5 The cells were seeded at a density of 100 cells / well in a 12-well plate coated with Matrigel and cultured, and the medium was changed every two days.
[0662] 9.2 Detection of Cell Markers in Universal Stem Cell-Derived iCMs
[0663] 9.2.1 FACS test results
[0664] Through the differentiation process of Example 9.1, obvious cell beating can be observed around D11 (day 11 of induced differentiation). HiPSC-derived cardiomyocytes were digested with tryple express for 30 minutes on days 15 and 30 of differentiation induction, and the cell suspension was collected, centrifuged, and washed with PBS. The cells were then fixed with 4% PFA at room temperature for 30 minutes, then blocked and permeabilized with a reagent (BD 554715) and incubated at room temperature for 10 minutes. The cTNT primary antibody (BD 564767) was diluted according to the instructions and added to the cells for incubation at room temperature for 1 hour. After washing twice with PBS to remove nonspecifically bound primary antibody, the cells were analyzed by flow cytometry. The results are shown in Figure 35. On D15 (the 15th day of induced differentiation), the proportion of cardiac troponin T (cTnT)+ cells in the iPS cell line WT cell group-derived cells was 71.91%, and the proportion of cTnT+ cells in the iPS cell line DKO+CD68 cell group-derived cells was 90.93%; on D30 (the 30th day of induced differentiation), the proportion of cTnT+ cells in the iPS cell line WT cell group-derived cells was 93.03%; the proportion of cTnT+ cells in the iPS cell line DKO+CD68 cell group-derived cells was 95.87%.
[0665] 9.2.2 qPCR test results
[0666] On day 30 of differentiation, the expression of cardiomyocyte-related genes was assessed by quantitative PCR. The procedure was as follows: the cell culture medium was aspirated, the cells were washed once with PBS, and 500 mL of Trizol was added to each well of a 12-well plate to lyse the cells. The cell lysate was collected into an RNase-free 1.5 mL EP tube. 100 mL of chloroform was added to each tube, and the tubes were vigorously vortexed for 15 seconds. After incubation at room temperature for 5 minutes, the tubes were centrifuged at 12,000 g for 15 minutes at 4°C. The supernatant was carefully aspirated into a new RNase-free 1.5 mL EP tube, an appropriate amount of isopropanol was added, and the tubes were gently inverted six times. After incubation at room temperature for 10 minutes, the tubes were centrifuged at 12,000 g for 10 minutes at 4°C. The supernatant was removed, the tubes were rinsed with 500 mL of pre-chilled 75% ethanol, and the tubes were centrifuged at 7,500 g for 5 minutes at 4°C. The ethanol was removed as much as possible, the tubes were left to air dry for 5 minutes, and 15-20 mL of DEPC water was added and placed on ice. After RNA was dissolved, the RNA concentration was determined using a NanoDrop analyzer. Reverse transcription was performed according to the instructions of the PrimeScript™ RT Master Mix kit. The reaction system was prepared on ice.
[0667] Reaction system (20 μL):
[0668] Reaction procedure:
[0669] The obtained cDNA can be stored at -20°C.
[0670] The fluorescent quantitative PCR reaction system was prepared using 2×SYBR Green qPCR Master Mix reagent.
[0671] Reaction system (20 mL):
[0672] Reaction procedure:
[0673] F+R primer sequence:
[0674] According to the Ct value given by the software, the difference in mRNA expression fold of the samples was calculated using the △△Ct algorithm.
[0675] As shown in FIG36 , the results show that CMs differentiated from iPS cell line WT cells and iPS cell line DKO+CD68 cells expressed cardiomyocyte-related genes, and the cardiomyocytes differentiated from iPS cell line DKO+CD68 cells expressed higher relative levels of genes except TNNI1.
[0676] 9.3 Detecting Cellular Function of Universal Stem Cell-Derived iCMs
[0677] 9.3.1 Universal stem cell-derived iCM calcium transient assay results
[0678] Calcium transients are one of the most representative functional parameters of cardiomyocytes. Excitation-contraction coupling in cardiomyocytes is driven by intracellular calcium oscillations. In adult cardiomyocytes, 70% of calcium influx is the result of Ca2+-induced Ca2+ release (CICR) via the sarcoplasmic reticulum (SR). Intracellular calcium is transported back to the SR via the sarcoplasmic / endoplasmic reticulum Ca2+ ATPase (SERCA) or removed from the cytosol via the Na+ / Ca2+ exchanger (NCX). Rhod-2AM is a cell membrane-permeable fluorescent dye. Its fluorescence intensity is very weak until it enters the cell and is cleaved. Once inside the cell, it is cleaved by intracellular esterases to form Rhod-2. Rhod-2 cannot penetrate the cell membrane and remains intracellular. Rhod-2 then binds to calcium ions and emits fluorescence, thus indicating dynamic changes in intracellular calcium ion concentrations.
[0679] On day 30 of differentiation induction, the cell culture medium was discarded, and 2 mL of cardiomyocyte maintenance medium was added to each well, along with 2 mL of Rhod-2AM stock solution (final concentration: 1 mM Rhod-2AM; Invitrogen, R1245MP, 20 x 50 mg). The cells were incubated at 37°C for 30 min to allow Rhod-2AM to penetrate the cell membrane and enter the cells. Fresh cardiomyocyte maintenance medium was then replaced with 2 mL per well. Spontaneous calcium transients of the cells were recorded at 37°C using a DeltaVision Ultra live cell workstation and system. Changes in calcium transients and related characteristic values (frequency, amplitude) of the cells within the field of view during the recording time were calculated using the DeltaVision Ultra correlation calculation software program. Each recording lasted at least 30 seconds. As shown in Figure 37 , by recording calcium transients, it was found that CMs differentiated from iPS cell line WT cells and iPS cell line DKO+CD68 cells both had regular and orderly calcium transients. Among them, the frequency and amplitude of calcium transients in CMs differentiated from iPS cell line DKO+CD68 cells within 30 s were significantly higher than those in CMs differentiated from iPS cell line WT cells.
[0680] 9.3.2 Validation of the Efficacy of Universal Stem Cell-Derived iCMs in a Permanently Ligated Mouse Myocardial Infarction Model
[0681] Myocardial infarction (MI) and acute coronary heart disease are among the most prominent causes of death in cardiovascular diseases. The MI mouse model with permanent ligation of the left anterior descending (LAD) coronary artery is very similar to human MI. The mouse surgical model of myocardial infarction by permanent LAD coronary artery ligation is highly reproducible and is currently the most widely used method for producing a mouse myocardial infarction model, providing a stable model basis for subsequent product efficacy verification. After the MI model is successfully produced, blood flow in most of the left ventricular myocardium stops. Insufficient myocardial oxygen supply can lead to ischemic death of cardiomyocytes. This pathological condition triggers a response in the ventricular tissue, ultimately leading to ventricular dysfunction, remodeling and heart failure. The steps for mouse modeling and iCM transplantation are as follows:
[0682] 1) Weigh NOG mice (Vitamin B, female) to determine the dose of anesthetic drugs and tidal volume of the ventilator. Preheat a heating pad at 37°C.
[0683] 2) 1.25% tribromoethanol was intraperitoneally injected into mice at a dose of 10 mL / g.
[0684] 3) Use depilatory cream to remove the hair on the throat and left side of the chest of the mouse.
[0685] 4) Check the depth of anesthesia by pinching the tail or hind legs and place the mouse in a supine position on a heating pad. Place a small gauze dressing under the animal's head to avoid overheating the eyes. Apply ophthalmic gel to prevent dryness of the eyes.
[0686] 5) Secure the limbs to the surface of the heating pad with tape. Pass a loop of 5-0 silk suture under the upper incisors and tape the end of the loop to the heating pad. Hold the animal's mouth open and perform oral intubation.
[0687] 6) Set the ventilator to a tidal volume of 2 mL and a respiratory rate of 125 breaths / min.
[0688] 7) Release the left forepaw from the tape and carefully move the mouse to the right side under the microscope. Once the animal is in the correct position, secure the left forepaw.
[0689] 8) Identify the dividing line between the left pectoralis minor and major muscles and make an oblique incision in the skin along this line with scissors. Use blunt microscissors to perform blunt dissection without cutting the pectoralis fascia.
[0690] 9) Use blunt forceps to open the chest cavity between the 3rd and 4th ribs, avoiding contact with the internal thoracic artery and causing massive bleeding, and do not touch the heart or lungs.
[0691] 10) Using fine curved forceps, carefully remove the pericardium and pull it apart without damaging the heart and lungs.
[0692] 11) Locate the left anterior descending (LAD) coronary artery. The LAD artery appears as a light red line (or may not be visible) extending from the left auricle edge to the apex of the heart.
[0693] 12.) Use a suture needle to pass a 7-0 silk suture under the LAD, 2-3 mm below the left atrium. Gently tighten the suture to avoid tearing the cardiac tissue (this position is considered the high ligature; the mid ligature is 1-2 mm below the high ligature, and the low ligature is 1-2 mm below the mid ligature). Do not enter the ventricular cavity too deeply or too shallowly. For sham-operated animals, pull the suture under the LAD and slowly remove it, avoiding tissue tearing. Grasp the third rib with forceps and suture twice under the third and fourth ribs with 5-0 silk suture.
[0694] 13) Place three drops of 0.9% saline solution over the opening and close the expiratory vent for 2 or 3 breaths to allow the lungs to inflate normally. Tighten the suture and secure.
[0695] 14) Suture the chest skin with two 5-0 silk sutures and secure it twice.
[0696] 15) After the mouse regains consciousness, place it in a cage and observe it regularly.
[0697] 16) Four days after the modeling is completed, a second thoracotomy is performed, and iCM is injected at three points around the infarct, with an injection volume of about 5-10 mL at each point, and a total of about 2 million cells. After that, the chest is closed according to the above steps and the status of the mice is observed. Two months after the cell injection, cardiac ultrasound function testing is performed (the instrument used is called ultra-high resolution small animal ultrasound imaging, its system model is vevo2100, and its manufacturer is Visualsonics). Echocardiography can be used to evaluate the structure and function of the heart in vivo. Related measurements include left ventricular wall thickness, inner diameter, mass, shortening fraction, and ejection fraction. After the mouse is anesthetized by depilating the chest and abdomen, cardiac ultrasound function testing is performed. The specific operations are as follows:
[0698] a) Imaging of the left ventricle in B-mode in the parasternal long-axis view;
[0699] b) Carefully adjust the mouse ultrasound stage to position the long axis of the left ventricle in the same plane as the ultrasound beam. During imaging, position the aortic valve and apex of the left ventricle in the same plane as the ultrasound beam. The aortic valve and apex serve as fixed points and remain constant between serial studies in the same animal.
[0700] c) Perform M-mode on the left ventricle to image the ventricle wall and interior;
[0701] d) After imaging, the following characteristic values are calculated based on the maximum ventricular contraction and relaxation amplitudes: ejection fraction (EF%), left ventricular internal shortening fraction (FS%), left ventricular end-systolic volume (LV Vol;s), and left ventricular end-diastolic volume (LV Vol;d).
[0702] In this example, the efficacy of the drug in mice with myocardial infarction was evaluated using cardiomyocytes induced and differentiated for approximately 30 days, following the aforementioned procedures. The efficacy of the drug in treating myocardial infarction was compared between a vehicle group and a DKO+CD68 group (i.e., a group treated with CM derived from DKO+CD68 iPS cells). Three mice were included in the sham group, three in the vehicle group, and three in the CM derived from DKO+CD68 iPS cells. The vehicle used was 5% human albumin and 95% electrolyte complex. As can be seen from Figure 38, DKO+CD68 cardiomyocytes have a significant effect on the recovery of mouse cardiac function. Compared with the vehicle group, the EF% value of the CM-treated group differentiated from the iPS cell line DKO+CD68 cells increased from 20.34% to 30.71%, the FS% value increased from 9.12% to 14.30%, the end-systolic volume decreased from 74.08 mL to 62.22 mL, and the end-diastolic volume decreased from 59.01 mL to 43.04 mL.
[0703] All data in this study are expressed as mean ± standard deviation (SD). Differences between groups were calculated using the Student's t-test, with P < 0.001 considered statistically significant. All data were graphed and analyzed using Graphpad Prism 8.0 software.
[0704] Example 10. Verification of low immunogenicity of universal stem cell-derived iCMs
[0705] The human pluripotent stem cells selected in this embodiment use CRISPR / CAS9 to knock out beta-2-microglobulin (B2M) in the endoplasmic reticulum, so that the cell surface MHC-I cannot form functional molecules, thereby escaping the killing of allogeneic CD8+T cells; By knocking out the positive regulator CIITA of MHC-II gene transcription, the expression of MHC-II class molecules is reduced, thereby escaping the killing of CD4+T cells. And CD68 is expressed in cells (DKO) with B2M / CIITA biallelic knockout by means of lentivirus to escape the killing of innate immunity. The cells successfully constructed are iPS cell lines DKO+CD68 cells, which are universal stem cells. Cardiomyocytes (iPS cell lines DKO+CD68-iCM) derived from universal stem cells should also have the ability to not activate the immune system and escape its killing.
[0706] 10.1 Determining the Retention of the Hypoimmunogenic Phenotype of Universally Derived Cells
[0707] iCMs differentiated from WT iPS cells and DKO+CD68 iPS cells were stimulated with IFN-γ: cells were plated in a well plate, and the next day, IFN-γ-containing medium was added to the cells during the medium change. After 48 hours, the cells were digested, and HLA-I / II expression was assessed by flow cytometry. As shown in Figure 39, iCMs differentiated from positive clones of the B2M / CIITA biallelic knockout iPS cell line DKO+CD68 stem cells remained negative for HLA-I / II expression and failed to upregulate HLA-I / II in response to IFN-γ stimulation.
[0708] 10.2 In vitro testing of the ability of universal derivative cells to escape immune system killing
[0709] 10.2.1 Universal Derivative Cells Resist Cytotoxicity by T+NK Mixed Lymphocytes (PBMC) in Vitro
[0710] A PBNK (IL-2-activated PBMC) cell cytotoxicity assay was performed on the XCelligence platform (ACEA BioSciences, San Diego, CA) to examine the immune evasion capabilities of universal derivatives (DKO+CD68-iCMs). Specifically, WT iPS cell lines and iCMs differentiated from DKO+CD68-iPS cell lines were resuspended in 100 μL of cell culture medium and plated onto 96-well E-plates coated with Matrigel (ACEA BioSciences). After the cell index reached 1, PBNK (IL-2-activated PBMCs) were added at a 1:1 E:T ratio. Data were normalized and analyzed using RTCA software (ACEA). As shown in Figure 40, only DKO+CD68-iCMs evaded cytotoxicity from PBNK (IL-2-activated PBMCs).
[0711] iPS cell line WT cells and iPS cell line DKO+CD68 cell-differentiated iCMs that were previously labeled with Dil (MCE; HY-D0083) were plated in 12-well plates. After 24 hours, the culture medium was discarded and PBNK (PBMC activated by IL-2) cells were added for co-culture. After 24 hours, the remaining iPS cell line WT cells and iPS cell line DKO+CD68 cell-differentiated iCMs after the removal of PBNK cells were observed, and the results are shown in Figure 41. Both bright field and fluorescence images showed that the surviving cells of iPS cell line DKO+CD68-iCM were significantly more than those of iPS cell line WT-iCM, indicating that iPS cell line DKO+CD68-iCM has a stronger ability to resist immune cell killing.
[0712] 10.2.2 In vitro detection of immune system activation
[0713] iPS cell line WT cells and iPS cell line DKO+CD68 cells differentiated iCM were plated in 12-well plates. After 24 hours, the culture medium was discarded and PBMCs labeled with CFSE (Invitrogen (Cat#C34554)) and phytohemagglutinin (PHA; Sigma L8902) (Holl V, et al. The major population of PHA-stimulated PBMCs infected by R5 or X4 HIV variants after a single cycle of infection is predominantly composed of CD45RO+CD4+ T lymphocytes. Arch Virol. 2007;152(3):507-18.) were added for co-culture. PHA was used as an activation stimulator for PBMCs. Flow cytometry was performed on the fifth day of co-culture to confirm whether iCMs stimulated PBMC proliferation. The results, as shown in Figure 42, showed that the percentage of PBMCs activated by PHA stimulation was 65.67%, 83.55% in the iPS cell line WT-iCM + PHA group, and 72.13% in the iPS cell line DKO + CD68-iCM group. This indicates that PHA-stimulated WT-iCM further stimulated PBMC proliferation, increasing it by 17.88%. In contrast, co-culture of iPS cell line DKO + CD68-iCM with PBMCs only increased PBMC proliferation by 6.46%, indicating that the ability of iPS cell line DKO + CD68-iCM to activate the immune system is significantly lower than that of WT-iCM.
[0714] Although the present invention has been disclosed above with reference to preferred embodiments, this is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
[0715] Sequence Listing
Claims
1. A low-immunogenicity pluripotent stem cell, comprising: reduced endogenous major histocompatibility class I antigen (MHC-I) function compared to parental pluripotent stem cells; Reduced endogenous major histocompatibility class II antigen (MHC-II) function compared to the parental pluripotent stem cell; and Reduced sensitivity to NK cell and / or macrophage killing compared to a parental pluripotent stem cell, wherein the reduced sensitivity to NK cell killing and / or macrophage killing is caused by increased expression of CD68 protein.
2. The low immunogenic pluripotent stem cell of claim 1, wherein the MHC-I function is reduced by reducing the activity of MHC-I class proteins or MHC-I transcriptional regulators.
3. The low immunogenic pluripotent stem cell according to claim 2, wherein the MHC-I class protein comprises an HLA-A protein, an HLA-B protein or an HLA-C protein. 4 . The low immunogenic pluripotent stem cell according to claim 2 , wherein the MHC-I transcriptional regulator comprises a B2M protein, a TAP1 protein, a TAP2 protein, a TAP-associated glycoprotein or a NLRC5 protein. The low immunogenicity pluripotent stem cell according to claim 2 , wherein the MHC-I function is reduced by reducing the activity of the B2M protein.
6. The low immunogenic pluripotent stem cell of claim 5, wherein the B2M protein is a human B2M protein comprising the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 1; or The B2M protein is a cynomolgus monkey B2M protein, which comprises the amino acid sequence shown in SEQ ID NO:9 or an amino acid sequence that has at least 90% identity with the amino acid sequence shown in SEQ ID NO:
9.
7. The low immunogenic pluripotent stem cell according to any one of claims 1 to 6, wherein the MHC-II function is reduced by reducing the activity of MHC-II class proteins or MHC-II transcriptional regulators. 8 . The low immunogenic pluripotent stem cell of claim 7 , wherein the MHC-II class protein comprises an HLA-DR protein, an HLA-DQ protein or an HLA-DP protein. 9 . The low immunogenic pluripotent stem cell of claim 7 , wherein the MHC-II transcriptional regulator comprises a CIITA protein, an RFXANK protein, an RFX5 protein or an RFXAP protein.
10. The low immunogenic pluripotent stem cell of claim 7, wherein the MHC-II function is reduced by reducing the activity of CIITA protein.
11. The low immunogenic pluripotent stem cell of claim 10, wherein the CIITA protein is a human CIITA protein comprising the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2; or The CIITA protein is a cynomolgus monkey CIITA protein, which comprises the amino acid sequence shown in SEQ ID NO: 10 or an amino acid sequence that has at least 90% identity with the amino acid sequence shown in SEQ ID NO:
10.
12. The low immunogenic pluripotent stem cell according to any one of claims 1 to 11, wherein the CD68 protein is a human CD68 protein comprising the amino acid sequence shown in SEQ ID NO: 3 or an amino acid sequence having at least 90% identity to the amino acid sequence shown in SEQ ID NO: 3; or The CD68 protein is a cynomolgus monkey CD68 protein, which comprises the amino acid sequence shown in SEQ ID NO:7 or an amino acid sequence that has at least 90% identity with the amino acid sequence shown in SEQ ID NO:
7.
13. The low immunogenic pluripotent stem cell of claim 1, comprising: One or more changes that reduce the activity of endogenous B2M protein; One or more changes that reduce the activity of endogenous CIITA protein; and One or more alterations result in increased expression of CD68 protein in the low immunogenic pluripotent stem cells.
14. The low immunogenic pluripotent stem cell according to claim 13, comprising: one or more alterations that inactivate both alleles of the endogenous B2M gene; One or more alterations that inactivate both alleles of the endogenous CIITA gene; and One or more alterations result in increased CD68 gene expression in the low immunogenic pluripotent stem cells.
15. A method for producing the low immunogenic pluripotent stem cell according to any one of claims 1 to 14, the method comprising: reducing endogenous major histocompatibility class I antigen (MHC-I) function in the pluripotent stem cells; reducing endogenous major histocompatibility class II antigen (MHC-II) function in the pluripotent stem cells; and The expression of a protein that reduces the sensitivity of the pluripotent stem cells to NK cell killing and / or macrophage killing is increased, wherein the protein is CD68 protein.
16. The method of claim 15, comprising: reducing the activity of B2M protein in the pluripotent stem cells; Reducing the activity of CIITA protein in the pluripotent stem cells; and The expression of CD68 protein in the pluripotent stem cells is increased.
17. The method of claim 16, comprising: Eliminating the activity of two alleles of the B2M gene in the pluripotent stem cells; Eliminating the activity of two alleles of the CIITA gene in the pluripotent stem cells; and The expression of the CD68 gene in the pluripotent stem cells is increased.
18. The method of claim 16 or 17, wherein the activity of the B2M protein in the pluripotent stem cells is reduced and / or the activity of the CIITA protein in the pluripotent stem cells is reduced by a technique selected from the following: Introduce gene expression modifying molecules, clustered regularly interspaced short palindromic repeats (CRISPR) technology, transcription activator-like effector nuclease (TALEN) technology, zinc finger nuclease (ZFN) technology or homologous recombination technology; preferably, the gene expression modifying molecules comprise siRNA, shRNA, microRNA, antisense RNA, antisense oligonucleotide ASO or anti-miRNA oligonucleotide AMO.
19. The method of claim 18, wherein Reducing the activity of B2M protein in the pluripotent stem cells by clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 gene editing technology; and / or The activity of CIITA protein in the pluripotent stem cells is reduced by clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 gene editing technology.
20. The method of any one of claims 15-19, wherein expression of the CD68 protein is increased by modification of an endogenous locus.
21. The method of any one of claims 15 to 19, wherein the expression of CD68 protein is increased by expression of a transgene; preferably, by synthesizing a nucleic acid sequence encoding CD68 protein to construct it into a lentiviral vector, and then introducing at least one copy of the CD68 gene under the control of a promoter into the pluripotent stem cells through the lentiviral vector to increase the expression of CD68 protein.
22. The method of claim 21, wherein the nucleic acid sequence encoding the CD68 protein comprises the nucleic acid sequence shown in SEQ ID NO: 4 or a nucleic acid sequence having at least 80% identity to the nucleic acid sequence shown in SEQ ID NO: 4; or The nucleic acid sequence of the CD68 protein comprises the nucleic acid sequence shown in SEQ ID NO:8 or a nucleic acid sequence having at least 80% identity with the nucleic acid sequence shown in SEQ ID NO:
8.
23. Use of the low immunogenic pluripotent stem cells according to any one of claims 1 to 14 or the low immunogenic pluripotent stem cells prepared by the method according to any one of claims 15 to 22 in the preparation of a medicament for preventing or treating a disease requiring cell transplantation; preferably, the disease comprises acute leukemia, chronic leukemia, lymphoma, myelodysplastic syndrome, multiple myeloma, small cell lung cancer, breast cancer, testicular cancer, neuroblastoma, ovarian cancer, melanoma, aplastic anemia, innate immune Defects, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, type I diabetes, Parkinson's disease, Alzheimer's disease, spinal cord injury, retinal degeneration, stroke, Huntington's disease, amyotrophic lateral sclerosis, atherosclerosis, hypertension, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, myocardial infarction, heart failure, aortic aneurysm, peripheral arterial disease, type II diabetes, scurvy, hypoglycemia, hyperlipidemia or osteoporosis.
24. A kit for preparing low immunogenic cardiomyocytes, the kit comprising the low immunogenic pluripotent stem cells according to any one of claims 1 to 14 or the low immunogenic pluripotent stem cells prepared by the method according to any one of claims 15 to 22, a first culture medium, a second culture medium and a third culture medium; The first culture medium is a basal culture medium containing a GSK-3 inhibitor; and The third culture medium is a basal culture medium containing a Wnt inhibitor.
25. The kit of claim 24, wherein The first culture medium is a basal culture medium containing a GSK-3 inhibitor and a B27 supplement without insulin; The second culture medium is a basal culture medium containing a B27 supplement without insulin; and / or The third culture medium is a basal culture medium containing a Wnt inhibitor and a B27 additive without insulin; Preferably, the basal medium comprises PRMI1640 basal medium; Preferably, the GSK-3 inhibitor comprises CHIR99021; Preferably, the Wnt inhibitor comprises at least one selected from IWR-1, IWP-2, IWP-4, and C59.
26. The kit according to claim 24 or 25, The kit further comprises a fourth culture medium, which is a basal culture medium comprising a B27 additive containing insulin, preferably, the basal culture medium comprises PRMI1640 basal culture medium; The kit further comprises a fifth culture medium, which is a basal culture medium comprising a ROCK inhibitor, preferably, the ROCK inhibitor comprises Y-27632, preferably, the basal culture medium comprises mTeSR1 basal culture medium; and / or The kit further comprises a sixth culture medium, which is a basal culture medium. Preferably, the basal culture medium comprises mTeSR1 basal culture medium.
27. A method for preparing cardiomyocytes with low immunogenicity, the method comprising using the kit according to any one of claims 24 to 26.
28. The method of claim 27, comprising: culturing low immunogenic pluripotent stem cells in a first culture medium; replacing the first culture medium with the second culture medium and continuing to culture the cells; The second culture medium was replaced with the third culture medium, and the cells were continued to be cultured; The third culture medium was replaced with the second culture medium, and the cells were continued to be cultured; and Obtain differentiated low-immunogenic cardiomyocytes; Preferably, the method comprises: Culturing low immunogenic pluripotent stem cells in the first culture medium for 2 days; The first culture medium was replaced with the second culture medium, and the cells were cultured for another day; The second culture medium was replaced with the third culture medium, and the cells were cultured for another 2 days; replacing the third culture medium with the second culture medium, and continuing to culture the cells for 10 days; and Obtain differentiated low-immunogenic cardiomyocytes.
29. The method of claim 27 or 28, The method further comprises culturing the low immunogenicity pluripotent stem cells in a fifth culture medium and / or culturing the low immunogenicity pluripotent stem cells in a sixth culture medium before culturing the low immunogenicity pluripotent stem cells in the first culture medium, and / or The method further includes culturing the differentiated low immunogenic cardiomyocytes in a fourth culture medium after obtaining the differentiated low immunogenic cardiomyocytes; Preferably, the method comprises: culturing the low immunogenic pluripotent stem cells in a fifth culture medium; The fifth culture medium is replaced with the sixth culture medium to continue culturing the low immunogenic pluripotent stem cells; replacing the sixth culture medium with the first culture medium, culturing the low-immunogenicity pluripotent stem cells in the first culture medium to induce them to differentiate into cardiomyocytes; replacing the first culture medium with the second culture medium and continuing to culture the cells; The second culture medium was replaced with the third culture medium, and the cells were continued to be cultured; The third culture medium was replaced with the second culture medium, and the cells were continued to be cultured; Obtain differentiated low-immunogenic cardiomyocytes; and culturing and maintaining differentiated low immunogenic cardiomyocytes in a fourth culture medium; More preferably, the method comprises: culturing the low immunogenicity pluripotent stem cells in the fifth culture medium for 1 day; The fifth culture medium was replaced with the sixth culture medium, and the low immunogenic pluripotent stem cells were cultured for another day; replacing the sixth culture medium with the first culture medium, culturing the low-immunogenicity pluripotent stem cells in the first culture medium for 2 days to induce differentiation into cardiomyocytes; The first culture medium was replaced with the second culture medium, and the cells were cultured for another day; The second culture medium was replaced with the third culture medium, and the cells were cultured for another 2 days; The third culture medium was replaced with the second culture medium, and the cells were cultured for another 10 days; Obtaining differentiated cardiomyocytes with low immunogenicity; and The differentiated low immunogenic cardiomyocytes were cultured and maintained in the fourth culture medium for 15 days.
30. A method for preparing low immunogenic cardiomyocytes, the method comprising: adding a GSK-3 inhibitor to a cardiomyocyte differentiation medium, and culturing the low immunogenicity pluripotent stem cells according to any one of claims 1 to 14 or the low immunogenicity pluripotent stem cells prepared by the method of any one of claims 15 to 22 in the cardiomyocyte differentiation medium to which the GSK-3 inhibitor is added; The cardiomyocyte differentiation medium supplemented with GSK-3 inhibitor was replaced with cardiomyocyte differentiation medium, and the cells were continued to be cultured; adding a Wnt inhibitor to the cardiomyocyte differentiation medium, and continuing to culture the cells in the cardiomyocyte differentiation medium supplemented with the Wnt inhibitor; The cardiomyocyte differentiation medium supplemented with Wnt inhibitors was replaced with cardiomyocyte differentiation medium and the cells were continued to be cultured; and Obtain differentiated low-immunogenic cardiomyocytes; Preferably, the cardiomyocyte differentiation medium is a basal medium containing a B27 additive without insulin, and more preferably, the cardiomyocyte differentiation medium is a PRMI1640 basal medium containing a B27 additive without insulin; Preferably, the GSK-3 inhibitor comprises CHIR99021; Preferably, the Wnt inhibitor comprises at least one selected from IWR-1, IWP-2, IWP-4, and C59; More preferably, the method comprises: CHIR99021 was added to the cardiomyocyte differentiation medium, and the low immunogenicity pluripotent stem cells were cultured in the cardiomyocyte differentiation medium supplemented with CHIR99021 for 2 days; The cardiomyocyte differentiation medium supplemented with CHIR99021 was replaced with cardiomyocyte differentiation medium, and the cells were cultured for another day; IWR-1 was added to the cardiomyocyte differentiation medium, and the cells were cultured for another 2 days in the cardiomyocyte differentiation medium supplemented with IWR-1; Replace the cardiomyocyte differentiation medium supplemented with IWR-1 with cardiomyocyte differentiation medium and continue culturing the cells for 10 days; and Obtain differentiated low-immunogenic cardiomyocytes; The cardiomyocyte differentiation medium is a PRMI1640 basal medium containing a B27 supplement without insulin.
31. The method of claim 30, further comprising culturing the low immunogenicity pluripotent stem cells in a basal medium comprising a ROCK inhibitor and / or culturing the low immunogenicity pluripotent stem cells in a basal medium not comprising a ROCK inhibitor before culturing the low immunogenicity pluripotent stem cells in a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor; and / or The method further comprises culturing and maintaining the differentiated low immunogenic cardiomyocytes in a cardiomyocyte maintenance medium after obtaining the differentiated low immunogenic cardiomyocytes; Preferably, the ROCK inhibitor comprises Y-27632; Preferably, the basal medium comprises mTeSR1 basal medium; Preferably, the cardiomyocyte maintenance medium is a PRMI1640 basal medium containing a B27 additive containing insulin; Preferably, the method comprises: Cultivating low immunogenic pluripotent stem cells in a basal medium containing a ROCK inhibitor; replacing the basal medium containing the ROCK inhibitor with a basal medium not containing the ROCK inhibitor, and continuing to culture the low-immunogenicity pluripotent stem cells; adding a GSK-3 inhibitor to a cardiomyocyte differentiation medium, replacing a basal medium not containing a ROCK inhibitor with a cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor, and culturing low immunogenic pluripotent stem cells in the cardiomyocyte differentiation medium supplemented with a GSK-3 inhibitor; The cardiomyocyte differentiation medium supplemented with GSK-3 inhibitor was replaced with cardiomyocyte differentiation medium, and the cells were continued to be cultured; adding a Wnt inhibitor to the cardiomyocyte differentiation medium, and continuing to culture the cells in the cardiomyocyte differentiation medium supplemented with the Wnt inhibitor; The cardiomyocyte differentiation medium supplemented with Wnt inhibitors was replaced with cardiomyocyte differentiation medium and the cells were continued to be cultured; Obtain differentiated low-immunogenic cardiomyocytes; and Cultivating and maintaining differentiated low-immunogenic cardiomyocytes in cardiomyocyte maintenance medium; More preferably, the method comprises: Low immunogenic pluripotent stem cells were cultured in mTeSR1 basal medium containing Y-27632; The mTeSR1 basal medium containing Y-27632 was replaced with the mTeSR1 basal medium not containing Y-27632, and the low immunogenic pluripotent stem cells were continued to be cultured; adding CHIR99021 to cardiomyocyte differentiation medium, replacing mTeSR1 basal medium not containing Y-27632 with cardiomyocyte differentiation medium supplemented with CHIR99021, and culturing low immunogenic pluripotent stem cells in cardiomyocyte differentiation medium supplemented with CHIR99021; Replace the cardiomyocyte differentiation medium supplemented with CHIR99021 with cardiomyocyte differentiation medium and continue culturing the cells; adding IWR-1 to the cardiomyocyte differentiation medium and continuing to culture the cells in the cardiomyocyte differentiation medium supplemented with IWR-1; Replace the cardiomyocyte differentiation medium supplemented with IWR-1 with cardiomyocyte differentiation medium and continue culturing the cells; Obtaining differentiated cardiomyocytes with low immunogenicity; and Cultivating and maintaining differentiated low-immunogenic cardiomyocytes in cardiomyocyte maintenance medium; The cardiomyocyte differentiation medium is a PRMI1640 basal medium containing a B27 additive without insulin, The cardiomyocyte maintenance medium is a PRMI1640 basal medium containing a B27 supplement containing insulin.
32. A low immunogenic cardiomyocyte prepared by the kit of any one of claims 24 to 26 or the method of any one of claims 27 to 31.
33. A cell therapeutic agent for preventing or treating heart disease, the cell therapeutic agent comprising the low immunogenic cardiomyocytes of claim 32.
34. The cell therapeutic agent of claim 33, wherein the heart disease is selected from the group consisting of myocardial infarction, angina pectoris, ischemic cardiomyopathy, primary cardiomyopathy, secondary cardiomyopathy and heart failure.
